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1. Introduction 
 
1.1 Tendon injury and healing process  
Tendons are dense connective tissues connecting muscle to bone, they transfer muscle forces onto bones 
and joints. For this function, tendons are composed of hierarchically organized collagen type I fibers 
providing the tendons’ ability to withstand great tensile forces. Tendon injuries may result in joint 
dysfunction because they oftentimes heal by production of an inferior tendon matrix and are prone to re-
occur. Tendon injuries are frequent medical problems in Traumatology and Orthopedics and mainly 
associate with overuse activity and age-related degeneration. Degenerative tendinopathy is considered one 
of the leading causes for tendon rupture and it also can result in unsuccessful healing response and 
increase risk of re-rupture (Yang et al., 2013). Degenerative tendinopathy (tendinosis) can be 
characterized by different tissue alterations and certain forms are enriched in cartilage nodules, 
disorganized extracellular matrix, ectopic bone, hypervascularity or mucoid deposits (Riley, 2008). 
Tendons are poorly vascularized tissues with a low density of specialized mesenchymal cells which 
exhibit low mitotic activities (Benjamin and Ralphs, 1997). Overall, tendons have a slow turnover of their 
cellular and extracellular matrix content, therefore, tendon natural healing process is extremely low and 
inefficient especially in the elderly (Marsolais and Frenette, 2005). Calcifying tendinosis is described by  
calcium deposits within tendon proper and/or insertions, which can furthermore exert inflammation, pain, 
swelling, redness and limited motion (Rui et al., 2011). 
Tendon healing includes three consecutive stages: inflammation, proliferation and remodeling (Fig. 1) 
(Docheva et al., 2015). The remodeling stage includes two sub-stages: consolidation and maturation. This 
stage is time consuming and is characterized by a decrease in cellular density, significant cell shape 
flattening, improved cell alignment to the axis of mechanical stretch, which is further accompanied by 
maturation of collagen type I and elastic fibers. Additional features of this stage are decreasing of 
biglycan and increasing of decorin and lumican protein expression (Juneja and Veillette, 2013). In 
parallel, collagen and elastic fibers start to organize along the longitudinal axis of the tendon, thereby 
restoring tendon stiffness and tensile strength (Sharma and Maffulli, 2005). The whole healing process 
after injury can go up to 1–2 years depending on the age and condition of the patient (Docheva et al., 
2015) . Moreover, the number of tendon clinical interventions per year is constantly increasing, which is 
in a positive relation to the rising sports participation and aging population in USA and Europe (Butler et 
al., 2004; Hess, 2010; Lantto et al., 2015). Certain tendons (Achilles, rotator cuff, patella and forearm 
extensors) are particularly susceptible to degeneration and surgical treatment (Docheva et al., 2015). Until 
now, the standard therapeutic options used for tendon repair comprise of surgical suture, cryotherapy, 
physiotherapy (including massage and controlled motion), shock-wave therapy, eccentric exercise 
therapy, autografts, allografts or synthetic prostheses; however, none of these alternatives has provided a 
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successful long-term solution and full regain of the tendon tissue quality and function particularly in aged 
individuals (Hsieh et al., 2016a). 
 
Fig. 1: The tendon repair process in humans. Four cartoon images corresponding to the main steps of tendon 
healing. Key cellular, matrix and molecular changes occurring in this process are described and graphically 
annotated. Based on (Beredjiklian, 2003) and (Docheva et al., 2015). 
 
1.2 Tendon tissue engineering   
The poor repair capacity of tendon requires novel strategies to speed up the healing process and to 
maximize the functional outcome. The successful healing of tendon injuries depends on various factors, 
including anatomical position, patient aged and physical condition, blood vessel supply, the depth and 
width of the wound and the amount of tissue loss. Although spontaneous healing can occur, this often 
results in scar tissue formation which is morphologically, biochemically and biomechanically different 
and inferior to healthy tendon tissue. These ultimately influence the functionality of the repaired tissue 
(Galvez et al., 2014; Yang et al., 2013). Hence, new and prospective developments in tissue engineering 
become increasingly important. The field of tissue engineering is highly multidisciplinary and spans from 
cell biology, molecular biology, medicine, and material science to mechanical engineering. In principle 
tendon tissue engineering relies on reparative cells, alone or in combination with biocompatible scaffolds, 
which are delivered during patient’s surgery into the site of tissue damage (Hsieh et al., 2016a). For the 
clinical need further research in the stage of pre-clinical development and optimization is needed (Fig. 2) 
(Docheva et al., 2015). Therefore, selecting the most appropriate cell type is one of the essential factors to 
be considered in cell-based tissue engineering.  
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Fig. 2: The current strategies for tendon tissue engineering, future challenges and translation to clinics. Matrix, cells 
and signals are the three major elements of tissue engineering approaches to tendon repair. In vitro tissue 
conditioning, in vivo implantation and clinical application are three research parts of clinical translation for tendon 
tissue engineering.  
 
 1.3 Stem cell sources  
Stem cells come from a variety of sources including embryonic stem cells (ESC), induced pluripotent 
stem cells (iPS cells) or adult stem cells (Fig. 3). ESC presented in the early embryo has one main 
disadvantage that is tendency to form teratomas. IPS cells are formed by co-expression of certain genes 
from adult somatic differentiated cells (Takahashi and Yamanaka, 2006). Using iPS cells avoids the 
ethical matters, but at present the technology is inefficient in generating large number of cell and not yet 
fully developed for clinical trials as well as there are still some concerns about tumor formation in vivo. 
Therefore, adult stem cells from autograft tissue are another more suitable and attractive cell type 
circumventing the ethical issues of ESC. The optimal cell type has to be able to adhere to the defect, 
differentiate to tissue-specific cells or exert stimulatory functions and trophic support to local progenitors. 
In addition, the function of the reparative cells can be enhances by growth factors or by genetic 
modification. Among the adult stem cell the best know so far are the one deriving from bone marrow. 
Concerning the use of bone marrow mesenchymal cells (BM-MSC) in tendon tissue engineering, one 
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advantage is that they can be obtained easier than tendon-derived stem/progenitor cells; via bone marrow 
aspirate from the iliac crest or femoral head. Furthermore, BM-MSC are well characterized and largely 
studied in various in vivo models. However, when used for repair of tendon tissue BM-MSCs, without 
tenogenic pre-differentiation, frequently lead to ossification, thereby worsening the tendon healing 
(Docheva et al., 2015). Regarding tendon -derived cells application of autologous cell will avoid immune 
complications but the patient has to undergo extra surgery to obtain a tendon biopsy for purification of 
tendon cells causing comorbidity, therefore such use is not foreseeable in clinics. Application of 
allogeneic cells may be easier to obtain from cadavers but may lead to immune reactions. Furthermore, 
tendon-derived cells undergo a phenotypic drift during in vitro prolonged cultivation (Kohler et al., 2013; 
Schulze-Tanzil et al., 2004; Yao et al., 2006). Bi et al., 2007 (Bi et al., 2007) were the first to compare the 
performance of BM-MSC to tendon-derived stem and progenitor cells (TSPC). This study showed that 
when the cells were applied in vivo, BM-MSC and TSPC behaved differently. TSPC formed tendon-like 
structures whereas BM-MSC formed bone-like structures. However, in this study, the cells were not tested 
in a clinically relevant tendon defect model.  
Dental stem cells have been discovered in the last years, such as postnatal dental pulp stem cells, 
periodontal ligament stem cells, tooth germ progenitor cells, gingival MSCs, etc. (Liu et al., 2015). These 
dental tissue-derived MSCs not only display self-renewal and multipotential but also possess 
immunomodulatory functions and potent tissue regenerative properties (Hakki et al., 2015; Lei et al., 
2014; Liu et al., 2015). Recently, several groups, including our, reported that periodontal ligament 
contains endogenous stem/progenitor cells (PDL) (Bluteau et al., 2008; Docheva et al., 2010; Ivanovski et 
al., 2006). PDL are simply harvested from extracted teeth when patients have orthodontic treatments 
(Miura et al., 2003; Seo et al., 2004).  
In order to investigate the most suitable adult stem cell types for tendon tissue engineering, we have 
established the isolation and cultivation of stem/progenitor cells from Achilles tendon (hAT cells) (Kohler 
et al., 2013) and periodontal ligament (PDL cells) (Docheva et al., 2010). These cells showed typical stem 
cell characteristics: they were positive for MSC surface markers (CD105, CD90 and CD73) and were able 
to differentiate into adipogenic, chondrogenic and osteogenic lineages. In contrast to the BM-MSC, the 
hAT PDL cells expressed Scleraxis (Scx) and tenomodulin (Tnmd), genes that are typical tenogenic 
markers (Dex et al., 2016) 
Genetically modifying MSCs prior to implantation may decrease the risk of ectopic bone formation as 
well as improve the performance of the cells. For example, he overexpression of the so far known tendon 
transcription factors, namely early growth response protein 1, Scx, and Mohawk in MSC have been 
reported to by us and others to lead to tenogenic differentiation prior to delivery (Guerquin et al., 2013; 
Alberton et al., 2012; Gulotta et al., 2011; Liu et al., 2015). In 2012, we genetically modified BM-MSC 
via lentiviral transduction of Scx cDNA (hMSC-Scx cells). We demonstrated that Scx overexpression was 
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successfully achieved and second, it resulted in reduction of self-renewal potential, loss of osteogenic and 
chondrogenic differentiation potential, and upregulation of Tnmd and other tendon-related genes. Thus, 
we concluded that the hMSC-Scx cells differentiated in tendon/ligament progenitors (Alberton et al., 
2012).  
 
Fig. 3: Candidate stem cells types for tendon tissue engineering. 
 
1.4 Objectives of the study 
As discussed in the introduction due to the global population aging, age-related degeneration, traumatic 
sport injuries and the weak repair potential of tendons, tendon conditions still present major challenges to 
orthopedic medicine. A novel approach to treat tendon injuries is with tissue engineering, in which 
reparative cells are introduced into the defect in order to enhance the repair and to fully restore the 
original tissue strength and function. In this approach a critical step is to identify the most appropriate cell 
types. Previously we have (Pietschmann et al., 2013) established a clinically relevant full-size Achilles 
tendon defect model in Rattus norvegicus. Therefore, the main aims of the doctoral thesis study were to 
investigate the potential of two novel and promising candidates’ namely (1) Scleraxis-programmed tendon 
progenitors (hMSC-Scx cells) and (2) periodontal ligament-derived cells (PDL cells) in our in vivo model 
and to evaluate the effects of these two cell types on tendon repair in the critical late remodeling phase. 
 
1.4.1 Publication 1 
Scaffold-free Scleraxis-programmed tendon progenitors aid in significantly enhanced repair of full-
size Achilles tendon rupture 
In the recent years the interest towards tendon development and repair mechanisms has greatly increased. 
During embryonic development, tendon and ligaments, in the axial skeleton, descend from a sub-
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compartment of the sclerotome called syndetome. The tendon progenitors, which are defined by the 
expression of the transcription factor Scx, derive from uncommitted mesenchymal progenitors, (Alberton 
et al., 2012). Scx is a member of the basis helix-loop-helix (bHLH) transcription factor family to which 
belong muscle key transcription factors MyoD and Myogenin. At embryonic day 15.5, Scx transcripts 
become more restricted to tendons and ligaments and remain such during adulthood (Asou et al., 2002). 
Moreover, Murchison et al.; 2007 (Murchison et al., 2007), have shown that gene knockout of Scx in Mus 
muculus, leads to a severe tendon and ligament phenotype. Furthermore, Scx is a tensile force-inducible 
gene in association with PDL fibrogenesis and maturation under tensile stress transmitted from 
physiological and orthodontic conditions (Takimoto et al., 2015). Thus, confirming the indispensable role 
of Scx for tendon and ligament development and function.  
Hence, in our study we aimed to fully explore the potential of a scaffold-free delivery of hMSC-Scx cells 
in contributing to tendon repair by utilizing our clinical full-size defect model in rat Achilles tendons. 
(Pietschmann et al., 2013) and carrying out in-depth histo-morphometric examinations after 16 weeks of 
cell implantation. We selected this time point in order to assess the long-term effect of the cells and how 
advanced is the critical late remodeling phase of tendon healing (Hsieh et al., 2016a).  
We have already established a tendon rupture model in a Foxn1nu athymic rat strain (Rattus introduced 
norvegicus) (Pietschmann et al., 2013). The model consisted of a surgical removal of three millimeter 
tissue from the Achilles tendon proper. The defects were reconnected by Kirchmayr–Kessler suture and it 
was filled by a three dimensional cell pellet of 1x106 cells (Fig.1A of publication 1). Four different study 
groups were generated (with ten animals per group): group (1) – included non-injured tendon (native 
tendon, NT); group (2) – control group consisting of animals with empty defect (ED); groups (3) and (4) – 
in which the animals received non- (hMSC-Mock) or Scx-modified (hMSC-Scx) cell pellets, respectively. 
In each animal only one hind limb was subjected to operation and 16 weeks were given for repair. The 
whole calcaneus-Achilles-gastrocnemius complexes of the rats were obtained from all groups and were 
used for various molecular and histological analyses. 
First, the gross morphological appearances and point-based scoring system showed that hMSC-Scx group 
had smaller mean tendon width and superior composition of the healed Achilles tendons. Next, by 
performing nuclear morphology and cell density studies, we concluded that tendons, which received our 
engineered cells after injury contain more tendon-like cells pointing towards an early maturation and 
advance healing. Third, the X-ray images and bone-related protein marker analysis revealed that the 
hMSC-Scx group has the smallest ossification area when compared to the ED and hMSC-mock groups. 
Then, periodic acid schiff (PAS) and Safranin O (S.O) staining demonstrated that the hMSC-Scx group 
has decreased ectopic fibrocartilage formation and very low proportion of mucopolysaccharides within the 
defect site. Lastly, the results of polarized light microscopy and immunohistological analyses indicated 
that hMSC-Scx group has higher collagen I, decorin, lumican, elastin levels and advanced matrix 
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maturation, hence making this study group the closest to the NT. In addition, using human-specific gene 
PCR and immunohistochemical staining for human antigen, we also confirmed the existence, localization 
and integration of the human cells into the injured tissue even after 16 weeks, suggesting their direct 
contribution to the healing. Taken together, we concluded that hMSC-Scx cells carry out powerful tendon 
inducing and differentiating properties and their implantation results in faster and better tendon repair; 
thus, making them very suitable for reconstruction of full-size tendon defects.  
In future, in order for hMSC-Scx cells, or variants of this technology, to become a factual clinical tool in 
orthopedics several open questions have to be addressed, such as possible combination and optimization 
with biomaterials/carriers; understanding the exact fate and survival rate of implanted cells; examining 
stable programming via transient Scx expression in autologous and allogenic cells; long-term functional 
and biomechanical performance tests in big animal models without immunosuppression. We believe that 
the present and forthcoming results on the application of Scx-based cell therapy can lead to improve 
outcomes of tendon healing (Hsieh et al., 2016a). 
 
1.4.2 Publication 2 
Periodontal ligament cells as alternative source for cell-based therapy of tendon injuries: in vivo 
study of full-size Achilles tendon defect in a rat model 
Periodontal ligament is a novel attractive cell source because it can be obtained from exfoliated deciduous 
teeth of children aged 5 onwards and from sound teeth that are normally discarded in frequent routine 
orthodontic procedures (premolars in class II malocclusion or wisdom teeth removal) in dental clinics. 
Patient-specific PDL cells can be easily harvested by scratching the surface of the root and in vitro pre-
expanded to high numbers in simple standard culture conditions. Possible bacterial, fungal or mycoplasma 
contamination can be easily controlled by using antibiotics, antifungal agents or elimination kits. 
Harvested PDL cells can thereafter be stored up for years ahead and last the phenotype of the cells is very 
similar in nature to tendon cells, hence no complicated genetic modification or growth factor 
manipulations are required. Therefore, the PDL can be considered an ideal source for stem cell banking 
and be used in therapy of tendon injuries (Hsieh et al., 2016b).  
Here, the same Achilles tendon defect model as publication 1 and similar experimental group design have 
been used with four study groups: group (1) –non-injured tendon (native tendon, NT); group (2) –empty 
defect tendon (ED); groups (3) and (4) –with PDL or hAT cell pellet implantation, respectively.  
First, macroscopic observation and H&E staining presented that PDL and hAT groups have smaller mean 
width and larger tendinous areas with well-organized collagen fibers. Second, PAS and S.O staining 
demonstrated that the remnant cartilaginous areas within the defect site are almost resorbed in PDL and 
hAT groups. Next, antibody-based stainings for collagen type I and III, polarized light microscopy and 
ELISA assays for collagen type I proved that the repaired tendons of PDL group had similar collagen 
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organization to hAT group and significantly better than ED group. Third, the results of 
immunohistological stainings (biglycan, decorin, lumican and elastin) and ELISA assays for biglycan and 
lumican demonstrated that the repaired tendons of PDL group had comparable matrix maturation to hAT 
group and advanced one to ED. Lastly, the results of cell density and angular deviation investigations 
showed close cell morphometry PDL and hAT groups to NT. Moreover, the implanted PDL and hAT cells 
were detected by human-specific immunohistochemical staining suggesting direct contribution as well as 
long-term survival in the defect area. Taken together, we concluded that the PDL cells aid in tendon 
healing in very similar fashion to hAT cells and therefore, can be considered as attractive alternative 
source for cell-based therapy of tendon injuries. Several open questions remain to be clarified in following 
investigations such as possible combination of PDL cells with suitable biomaterials; the scaling up to 
dimensions similar to human tendon injuries; the reached biomechanical strength; the risk of PDL cell 
quality loss after long-term storage; the exact technique and time point of application; and the prognosis 
on periods for patient hospitalization and post-operative physiotherapy. It will be of great interest, by 
using adequate animal models, to examine wheatear PDL-derived cells are also suitable for prevention or 
therapy of tendon/ligament degenerative diseases, that are occurring prior rupture, and for periodontitis. 
We trust that further research on these questions will be critical to translating our animal model to 
potential clinical applications (Hsieh et al., 2016b).  
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2. Summary 
 
Introduction: Current treatment options of injured tendons mostly include surgical interventions, tendon 
transfer or conservative therapy; however, frequently they do not provide satisfactory results and the 
repair process is very lengthy. Moreover, the patient’s quality of life is majorly affected and injury 
relapses may occur. Cell-based tendon tissue engineering is attractive alternative approach to speed up 
and augment tendon repair. Choosing the most appropriate cell type is essential in this application as it 
can greatly affect the success of the therapy. At present, there are various obstacles of using certain 
subsets of adult stem cells such as mesenchymal stem cells (MSC) from bone marrow (BM) and tendon-
derived cells in tendon engineering. We have previously established and characterized mesenchymal stem 
cells, which are genetically modified with tendon-specific transcription factor Scleraxis (hMSC-Scx) as 
well as patient-derived periodontal ligament cells (PDL). Here, the main goal was to evaluate the repair 
potential of these cell types in a clinically relevant rat full-size Achilles tendon defect and to evaluate their 
benefits on tendon repair at the critical remodeling stage of the tendon healing process. 
Materials & Methods: Cells were pre-expanded using standard culture conditions and pelleted prior 
implantation in scaffold-free fashion. Four study groups were design for the evaluation of each cell type 
(controls: native tendon (NT, non-injured Achilles tendon); empty defect (ED, consisting of injured 
Achilles tendon without cell implantation); hMSC-Mock (implanted with cells expressing mock 
transgene); hAT (implanted with Achilles tendon-derived cell line) and full-size tendon injury model was 
applied as described by us in (Pietschmann et al., 2013). In brief, the model consists of: 1) a surgical 
removal of three millimeters tissue from the Achilles tendon proper; 2) reconnection of the tendon ends by 
Kirchmayr–Kessler suture; 3) administration of cell pellet; 4) post-implantation pellet adherence for 5 min; 
and 5) skin closure. The Achilles tendons were harvested for detail histological and molecular evaluation 
at 16 weeks after surgery.  
Results: Evaluating hMSC-Scx healing potential. Firstly, quantitation of the Achilles tendons dimensions 
was used to assess the gross morphological appearances in four experimental groups. We found that the 
hMSC-Scx group had significantly smaller mean tendon width compared with the ED group. Next, we 
applied H&E and elastin staining for point-based scoring system. Our scoring data clearly showed that the 
hMSC-Scx group had a superior composition of the healed Achilles tendons that is closer to the NT group. 
We investigated the cellular alignments, cell flattening and cell density by H&E- and DAPI-stained 
images and the quantification results showed that the hMSC-Scx group had better nuclear orientation 
angles, lower cellular density and higher abundance of flattened cells compared to the ED and hMSC-
Mock groups. Additionally, using x-ray and osteopontin stained images; we demonstrated that the hMSC-
Scx group had the least degree of calcification in comparison to the ED and hMSC-Mock groups. Finally, 
based on the combination of various histological (periodic acid schiff and Safranin O staining), polarized 
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light microscopy and immunohistological analyses of critical tendon matrix proteins (type I, III collagen, 
biglycan, decorin, lumican and elastin), the hMSC-Scx group demonstrated superior repair, more 
organized collagen fibers and advanced matrix maturation of the injured tendons, making this study group 
the closest to the native non-injured tendon. Via two different techniques for in vivo tracking, namely 
forensic genomic PCR and antibody-based detection, we could demonstrate that the human cells are 
retained within the implanted area and that a portion of these cells or their progeny can survive as long as 
16 weeks post-surgery. Thus, our hMSC-Scx cells not only can form tendon-like structures, but can 
directly contribute to enhanced tendon healing in a clinically relevant Achilles tendon injury model. 
Evaluating PDL healing potential. The gross appearance and H&E-stained mosaic images, PDL-
implanted Achilles tendons suggested that this group performs comparably to the hAT group, but also is 
superior to the non-implanted injured tendon group, ED. PDL groups exhibited smaller mean tendon 
width compared to the ED group. Next, matrix histology, bone marker osteopontin staining and 
quantitation of X-ray images revealed that the implantation of either PDL or hAT cells was advantageous 
for the tendon healing process. Based on various immunohistological analyses (type I, III collagen, 
biglycan, decorin, lumican and elastin), polarized light microscopy and ELISA quantitation (type I, III 
collagen, biglycan and lumican), we concluded that the PDL group, similar to the hAT group, has more 
mature and organized matrix protein composition than the ED group. Last, we evaluated the cell density 
and cellular alignment as described above and our results showed that the PDL group had lower cell 
density and better parallel alignment than the ED group. Furthermore, the implanted human cells or their 
progeny were detectable by human-specific antigen HLA-ABC, thus suggesting long-term integration in 
the tendon. In sum, PDL cells can become very attractive novel cell source for tendon and ligament 
therapy due to their easier collection from orthodontic procedure and banking up for later use in clinics. 
Conclusion: Our in-depth results demonstrated that hMSC-Scx and PDL cells implantation in injured 
tendons leads to superior tissue maturation, more organized collagen fibres and better tissue/cell 
morphometric parameters when compared with the non-implanted tendons. Taken together, the outcomes 
suggest that hMSC-Scx and PDL cells exert strong tendon inductive and repair properties making them 
well suited for reconstruction of tendon defects. 
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3. Zusammenfassung 
 
Einleitung: Aktuelle Behandlungsmöglichkeiten von verletzten Sehnen umfassen vor allem chirurgische 
Eingriffe, Sehnenübertragung oder konservative Therapie; jedoch liefern häufig diese Eingriffe kein 
zufriedenstellendes Ergebnis und der Reparaturprozess ist sehr langwierig. Darüber hinaus ist die 
Lebensqualität des Patienten stark beeinträchtigt und Verletzungen können wiederauftreten. Zell-basierte 
Sehnen-Tissue-Engineering ist eine attraktive Ansatzalternative zur Beschleunigung und Verbesserung 
von Sehnenreparaturen. Die Wahl des am besten geeigneten Zelltypen ist von wesentlicher Bedeutung zur 
Anwendung, da es großen Einfluss auf den Erfolg der Therapie ausübt. Derzeit gibt es verschiedene 
Hindernisse bei der Verwendung bestimmter Stammzellpopulationen adulter Stammzellen, wie 
mesenchymale Stammzellen (MSC) aus dem Knochenmark (BM) und Sehnen abgeleiteten Zellen in der 
Sehnen-Tissue-Engineering. Wir haben zuvor mesenchymale Stammzellen etabliert und charakterisiert, 
die mit dem Sehnenspezifischen Transkriptionsfaktor Scleraxis (hMSC-Scx) modifiziert sind wie auch 
parodontale Ligamentzellen (PDL). Hier war das Hauptziel, das Reparaturpotenzial dieser Zelltypen in 
einem klinisch relevanten Achillessehnendefekt der Ratte zu beurteilen und ihre Vorteile bei der 
Sehnenreparatur im kritischen Remodelierungsstadium des Sehnenheilungsprozesses zu bewerten. 
Materialien & Methoden: Die Zellen wurden unter Standardkulturbedingungen vorexpandiert und vor der 
Implantation in gerüstfreier Weise pelletiert. Es wurden vier Studiengruppen für die Beurteilung der 
einzelnen Zelltypen (Kontrollen: native Sehne (NT, nicht verletzte Achillessehne), leerer Defekt (ED, 
bestehend aus verletzter Achillessehne ohne Zellimplantation: hMSC-Mock (implantiert mit Zellen))und 
das Sehnenverletzungsmodell in voller Größe angewendet wie bereits beschrieben in (Pietschmann et al., 
2013). Kurzgefasst, das Modell besteht aus: 1) einer chirurgischen Entnahme von drei Millimeter Gewebe 
von der eigentlichen Achillessehne; 2) Wiederverbindung der Sehnenenden durch Kirchmayr-Kessler-
Naht; 3) Verabreichung von Zellpellets; 4) Post-Implantation eine Pellet-Adhärenz für 5 min; und 5) 
Hautverschluss. Die Achillessehnen wurden zur detaillierten histologischen und molekularen Auswertung 
nach 16 Wochen nach der Operation entnommen. 
Resultate: Auswertung des Heilpotenzials der hMSC-Scx. Zunächst wurde die Quantifizierung der 
Achillessehnenmaße verwendet, um die groben morphologischen Erscheinungen der vier experimentellen 
Gruppen zu beurteilen. Wir stellten fest, dass die hMSC-Scx-Gruppe eine signifikant kleinere mittlere 
Sehnenbreite aufwies als die ED-Gruppe. Als nächstes verwendeten wir H&E und Elastin-Färbung für ein 
Punkt-basierendes Bewertungssystems. Unsere Bewertungsdaten beweisen deutlich, dass die hMSC-Scx-
Gruppe eine überlegene Zusammensetzung der geheilten Achillessehnen nachweist, die näher an der NT-
Gruppe ist. Wir untersuchten die zellulären Ausrichtungen, die Zellabflachung und Zelldichte durch 
H&E- und DAPI-gefärbte Bilder. Die Quantifizierungsergebnisse zeigten, dass die hMSC-Scx-Gruppe 
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bessere Kernorientierungswinkel, geringere Zelldichte und höhere Häufigkeit von abgeflachten Zellen im 
Vergleich zu den ED- und hMSC-Mock-Gruppe nachwies. Anhand von Röntgen-und Osteopontin 
gefärbten Bildern bewiesen wir dass die hMSC-Scx-Gruppe den geringsten Grad der Verkalkung im 
Vergleich zu den ED- und hMSC-Mock-Gruppen aufweist. Abschließend, basierend auf die Kombination 
verschiedener histologischer (Periodsäure-Schiff- und Safranin-O-Färbung), polarisierter 
Lichtmikroskopie und immunhistologischer Analysen kritische Sehnenmatrixproteine (Collagen Typ I 
und III, Biglycan, Decorin, Lumican und Elastin), zeigte die hMSC-Scx Gruppe deutlich überlegene 
Reparatur, mehr organisierte Kollagenfasern und erweiterte Matrix-Reifung der verletzten Sehnen,somit 
zeigte sich diese Studiengruppe der nativen, nicht verletzten Sehne am nahsten. Durch zwei verschiedene 
Techniken für die in vivo-Verfolgung, nämlich forensische genomische PCR und den Antikörper-
basierten Nachweis, konnten wir belegen, dass die menschlichen Zellen innerhalb des implantierten 
Bereichs zurückgehalten werden und dass ein Teil dieser Zellen, oder deren Nachkommen, bis zu 16 
Wochen nach dem chirurgischen Eingriff überleben können. So können unsere hMSC-Scx-Zellen nicht 
nur sehnenartige Strukturen bilden, sondern auch direkt zu einer verbesserten Sehnenheilung in einem 
klinisch relevanten Achillessehnenverletzungsmodell beitragen. 
Auswertung des Heilspotenzials von PDL. Anhand des gesamten Aussehens und H&E-gefärbte 
Mosaikbilder,  deuten PDL-implantierte Achillessehnen darauf hin, dass diese Gruppe vergleichbar mit 
der hAT-Gruppe ist, aber auch der nicht implantierten verletzten Sehnengruppe ED überlegen ist. PDL-
Gruppen zeigten eine kleinere mittlere Sehnenbreite im Vergleich zur ED-Gruppe. Als nächstes zeigten 
Matrixhistologie, Knochenmarker-Osteopontin-Färbung und Quantifizierung von Röntgenbildern, dass 
die Implantation von PDL- oder hAT-Zellen für den Sehnenheilungsprozess vorteilhaft war. Basierend 
auf verschiedenen immunhistologischen Analysen (Kollagen Typ I und III, Biglycan, Decorin, Lumican 
und Elastin), der polarisierten Lichtmikroskopie und der ELISA-Quantifizierung (Kollagen Typ I und III, 
Biglycan und Lumican) wurde festgestellt, dass die PDL-Gruppe, ähnlich der hAT Gruppe, mehr reife 
und organisierte Matrix-Protein-Zusammensetzung als die ED-Gruppe nachwies. Zuletzt haben wir die 
Zelldichte und die zelluläre Ausrichtung wie oben beschrieben evaluiert. Unsere Ergebnisse zeigten, dass 
die PDL-Gruppe eine niedrigere Zelldichte und eine bessere parallele Ausrichtung als die ED-Gruppe 
aufweist. Darüber hinaus konnten die implantierten menschlichen Zellen, oder ihre Nachkommen, durch 
human-spezifisches Antigen HLA-ABC nachgewiesen werden, was auf eine Langzeitintegration in die 
Sehne hindeutet. Zusammengefasst, können PDL-Zellen als eine sehr attraktive neue Zellquelle für 
Sehnen-und Ligamentherapie fungieren aufgrund ihrer einfacheren Sammlung von kieferorthopädischen 
Verfahren und Banken für die spätere Verwendung in Kliniken. 
Schlussfolgerung: Unsere eingehenden Ergebnisse zeigten, dass hMSC-Scx- und PDL-Zellimplantationen 
in verletzten Sehnen zu einer überlegenen Gewebereifung, mehr organisierter Kollagenfasern und besserer 
morphomertrischer Gewebe/Zellen Parameter führt im Vergleich zu den nicht implantierten Sehnen. 
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Zusammengenommen zeigen die Ergebnisse, dass hMSC-Scx und PDL-Zellen starke Sehnen induktive 
und Reparatur-Eigenschaften ausüben, wodurch sie gut für die Rekonstruktion von Sehnendefekten 
geeignet sind. 
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Aim: Currently there is no effective approach to enhance tendon repair, hence we 
aimed to identify a suitable cell source for tendon engineering utilizing an established 
clinically relevant animal model for tendon injury. Materials & methods: We 
compared, by in-depth histomorphometric evaluation, the regenerative potential of 
uncommitted human mesenchymal stem cells (hMSC) and Scleraxis (Scx)-programmed 
tendon progenitors (hMSC-Scx) in the healing of a full-size of rat Achilles tendon 
defect. Results: Our analyses clearly demonstrated that implantation of hMSC-Scx, in 
contrast to hMSC and empty defect, results in smaller diameters, negligible ectopic 
calcification and advanced cellular organization and matrix maturation in the injured 
tendons. Conclusion: Scaffold-free delivery of hMSC-Scx aids in enhanced repair in a 
clinically translatable Achilles tendon injury model.
First draft submitted: 20 October 2015; Accepted for publication: 16 February 2016; 
Published online: 13 April 2016
Keywords:  MESENCHYMAL STEM CELLS s Scleraxis s TENDON HEALING s TENDON PROGENITORS
Tendons injuries, consecutive to overuse or 
age-related degeneration, are common and 
present a clinical challenge in orthopedic 
medicine because of the lengthy periods of 
post-traumatic healing and functional gain, 
as well as the high rate of rupture recur-
rence [1,2]. Moreover, the number of tendon 
clinical interventions per year is constantly 
increasing, which is in direct relation to the 
rising population aging in Europe and the 
USA [3–5]. Certain tendons (Achilles, rota-
tor cuff, patella and forearm extensors) are 
particularly susceptible to degeneration and 
surgical treatment. The standard therapeutic 
options for tendons repair comprise of suture, 
autografts, allografts and synthetic prosthe-
ses; however, none of these alternatives have 
provided a successful long-term solution, 
especially in aged individuals [6].
Tendon tissue heals by initial formation 
of poor scar tissue which is then gradually 
remodeled over long periods of time [7–12]. In 
short, the healing involves three overlapping 
phases: an inflammatory stage, which occurs 
immediately after the tendon rupture; a pro-
liferation stage begins within the first days/
week and results in the of establishment scar 
tissue reconnecting the injured tendon ends; 
and a long remodeling stage including the 
two substages; consolidation and matura-
tion, initiating around 6 weeks after injury 
and goes up to 1–2 years depending on the 
age and condition of the patient [7–12]. Cel-
lularity and matrix production are gradually 
decreased during the consolidation stage 
followed by gradual increase of collagen 
fibril alignment and cross-linking over the 
extended period of the maturation phase [7–
12]. And precisely because tendon repair and 
rehabilitation requires lengthy periods, the 
field’s great interest is to accelerate these 
processes without loss of quality and func-
tion the de novo built tissue. Cell-based tis-
sue engineering is nowadays one of the most 
attractive and widely explored strategies for 
musculoskeletal regeneration. This approach 
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Figure 1. Investigation of Achilles tendon overall appearance and dimensions. (A) A schematic image of the 
established Achilles tendon injury model. (B) Representative gross morphological images of the four study groups, 
NT, ED, hMSC-Mock and hMSC-Scx after 16 weeks of healing. (C) The width, measured in the tendon proper, and 
(D) length of the Achilles tendons from the four groups. Bar chart present mean values ± standard deviations. 
**p = 0.002 hMSC-Scx vs ED (n = 10, 10 animals/group). 
B: Calcaneus bone; D: Surgery defect; M: Gastrocnemius muscle; P: Cell pellet; S: Surgical suture; T: Achilles 
tendon.
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relies on reparative cells, alone or in combination with 
biocompatible scaffolds, which are delivered during 
patient’s surgery into the site of tissue damage. There-
fore, selecting the most appropriate cell type is of 
utmost importance.
In tendon engineering, several cell types such as 
mesenchymal stem cells (MSC) from different tis-
sue sources and tendon-derived cells have been sug-
gested as suitable targets. However, the involvement of 
each of these cell types has to solve various challenges 
(reviewed in [7]). Bone marrow (BM)-MSC are the 
most frequently evaluated cell type due to well-estab-
lished collection protocols as well as being the best 
characterized cells; however, ectopic bone formation 
within the injured tendons is closely associated with 
BM-MSC implantation (reviewed in [7]). The main 
risks of autologous tendon cell applications are patient 
comorbidity and a phenotypic drift of the primary cells 
during the steps of in vitro expansion and validation 
([13,14], and reviewed in [7]).
Scleraxis (Scx) is a member of the basic helix-loop-
helix (bHLH) transcription factor family, which regu-
lates embryonic tendon formation and postnatal ten-
don function [15,16]. In 2012, we showed that a stable 
ectopic expression of Scx in BM-hMSC resulted in the 
generation of a homogeneous population of commit-
ted tendon progenitors [17]. In 2013 [18], we published 
the establishment of a very clinically relevant full-
size Achilles tendon injury model in Rattus norvegi-
cus. Recently, three studies, namely by Gulotta et al., 
Chen et al. and Tan et al., have tested whether Scx in 
combination with cells and carriers can promote early 
tendon repair up in animal models [19–21]. Hence, in 
our study we aimed to fully explore the potential of 
a scaffold-free delivery of hMSC-Scx cells in contrib-
uting to tendon repair by utilizing the above in vivo 
model [18] and carrying out in-depth histo-morpho-
metric examinations after 16 weeks of cell implanta-
tion. We selected this time point in order to assess the 
long-term effect of the cells and how advanced the 
critical late remodeling phase of tendon healing is.
Materials & methods
Cell culture
The well-established and characterized hMSC-Mock 
and hMSC-Scx cell lines were used in the study 
(described in [17]). These two cell lines were main-
tained in Alpha minimum essential medium Gluta-
MAX culture media (Gibco, Germany) supplemented 
with 10% fetal bovine serum (FBS, Sigma-Aldrich, 
Germany). Cells were cultured on polystyrene dishes 
in a humidified incubator at 5% CO2 and 37°C. 
Cells were expanded to sufficient for implantation 
cell numbers in three-five consecutive passages. Prior 
implantation, aliquots of hMSC-Mock and hMSC-
Scx were used for RNA isolation and polymerase chain 
reaction (PCR) validation of transgene expression 
(Supplementary Figure 1 & Supplementary data), which 
has been previously demonstrated in [17].
Animal model & surgical procedure
Surgical procedures were performed according to 
our established in vivo model with slight modifica-
tions [18]. All procedures for animal handling prior, 
during and after surgery were approved by the Ani-
mal Care and Use Committee of the Bavarian Gov-
ernment (animal grant no. 55.2-1-54-2531-58-08). 
Briefly, athymic female Foxn1nu rats were purchased 
from Charles River (Sulzfeld, Germany) and accom-
modated in the central animal facility. Four different 
study groups with ten rats per group were randomly 
selected from the colony: (1) Native tendon (NT), con-
sisting of noninjured left Achilles tendon; (2) Empty 
defect (ED) group, consisting of injured right Achilles 
tendon without cell implantation; (3) and (4) in which 
the animals received one-shot implantation of scaffold-
free Mock- (hMSC-Mock group) or Scx-hMSC pel-
lets (hMSC-Scx group) within injured right Achilles 
tendon, respectively. Cell centrifugation at 500 g for 
10 min was carried out to form a 3D cell pellet com-
prising of 1 × 106 cells. The surgical operation consisted 
of surgically removing three millimeters tendon tissue 
from the Achilles tendon proper (∼3 mm proximal 
from the calcaneus and 3 mm distal from the gastroc-
nemius muscle, average length of rat Achilles tendon is 
12 mm) (Figure 1A). Each defect was first reconnected 
by Kirchmayr–Kessler suture and then the 3D cell pel-
let was administrated with a cut sterile pipette tip and 
left to adhere for approximately 5 min (Figure 1A).
At 16 weeks after surgery animals were euthanased, 
gastrocnemius muscle – Achilles tendon – calcaneus 
bone units revealed by skin incision, imaged and width 
of tendon proper and total length of the Achilles ten-
dons were manually measured. Afterward tissue samples 
were explanted and processed as described below.
Histomorphometry
The gastrocnemius muscle – Achilles tendon – cal-
caneus bone units were fixed either in 4% parafor-
maldehyde (PFA; Merck, Germany) or in 95% etha-
nol/5% absolute acetic acid overnight at 4°C (each 
five animals/group). PFA-fixed sections were used 
for general histological and immunohistochemical 
stainings, while ethanol-fixed sections were used for 
immunohistochemistry with anticollagen antibod-
ies (Supplementary Table 1). After fixation, specimens 
were decalcified in 10% EDTA/PBS pH 8.0 (Sigma-
Aldrich, Germany) for four weeks at room tempera-
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ture, then treated with consecutive 10, 15 and 20% 
sucrose/PBS solutions at 4°C for 2 h and last, embed-
ded in tissue freezing medium (Jung, Germany), 
and cryosectioned longitudinally at 12 μm (Microm 
HM500 OM, Germany) allowing full exposure of the 
whole complex Gastrocnemius muscle- Achilles ten-
don-calcaneus. Prior use sections were stored at -20°C.
Selected sections (PFA-fixed) were stained with 
hematoxylin and eosin (H&E) [18], or periodic acid-
schiff (PAS) using well-established standard histo-
logical protocols or following manufacturer’s instruc-
tions (PAS staining system, Sigma-Aldrich). For the 
Safranin-O/Fast Green (S.O/F.G) staining [18,22], 
the sections were equilibrated to room temperature 
and hydrated with PBS 3× 5 min and then changed 
to deionized water. Next, the sections were placed in 
0.02% F.G (Sigma-Aldrich) in 95% ethanol for 12 
min, rinsed under 1% Acetic Acid for 5 min, immersed 
in 0.5% S.O (Sigma-Aldrich) for 15 min. Last, samples 
were rinsed quickly in 90% and 100% ethanol, and 
mounted with Entellan mounting medium (Merck).
For immunohistochemistry, selected sections were 
treated with 2 mg/ml hyaluronidase (Sigma-Aldrich, 
Germany) for 30 min at 37°C. After washing and 
blocking, primary antibodies were applied overnight 
at 4°C. Next day, corresponding secondary antibod-
ies were used for 1 h. For full details on blocking 
solutions and antibodies used in the study refer to 
Supplementary Table 1. For immunofluorescence-
based experiments, sections were shortly counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI) 
(Life technology, USA) and mounted with fluoroshield 
(Sigma-Aldrich, Germany). For 3,3′ diaminobenzi-
dine (DAB)-based experiments, an initial quenching 
step was performed using 4% H2O2/methanol for 30 
min at room temperature, and afterward the classical 
Point-based scoring system for histological and elastic fiber assessment in order to evaluate the progress of Achilles 
tendon repair.
Study 
group 
Scored parameters
I  
Cellularity
II  
Ectopic 
calcification
III  
Vascularized 
areas
IV  
Adipose 
areas
V  
Poor fibrous 
tissue
VI  
Elastic fibers
VII  
Total points
      Content Morphology  
NT 
Mean 4 4 3.5 2.95 4 4 4 26.45
Median 4 4 3.5 2.95 4 4 4 26.45
IQR 0 0 1 1.3 0 0 0  
ED
Mean 1 2.7 3.17 2.73 1.77 2.25 1.25 14.87
Median 1 3 3 2.6 1.65 2.5 1 14.75
IQR 0 1.1 0.25 0.55 1.475 2.25 0.75  
hMSC-Mock
Mean 1.24 2.72 2.76 2.5 1.5 2.5 1.75 14.97
Median 1.6 3 3 2.6 1.3 2.5 1.5 15.5
IQR 1.3 1.3 1.2 0.65 1.1 1 1.75  
hMSC-Scx
Mean 1.5 3.33 2.8 2.9 2.48 2.75 2.25 18.01
Median 1 3.15 2.8 3 2.65 3 2.5 18.1
IQR 1.5 0.825 1.6 0.3 2.78 0.75 1  
-EAN MEDIAN POINT VALUES AND )12 INTERQUARTILE RANGE	 OF SCORED POINTS ARE SHOWN
) %STIMATION OF INCREASE IN CELLULARITY COMPARED WITH NORMAL UNINJURED TENDON .4	
)) %STIMATION OF INCREASE IN AREAS WITH ECTOPIC CALCIlCATION COMPARED WITH .4
))) %STIMATION OF INCREASE IN VASCULARIZED AREAS COMPARED WITH .4
)6 %STIMATION OF INCREASE IN ADIPOSERICH AREAS COMPARED WITH .4
6 %STIMATION OF INCREASE IN AREAS WITH POOR lBER ORGANIZATION COMPARED WITH .4
6) %STIMATION OF INCREASE IN TOTAL AMOUNT OF MATURE ELASTIC lBERS COMPARED WITH .4
6)) 4HE SUM OF POINTS OF CLASSES )n6)
 POINTS  n  POINTS  n  POINTS  n AND  POINT  n &OR ELASTIN lBER MORPHOLOGY  POINTS  THIN PARALLEL ELASTIN lBERS WHILE  POINT 
 THICK IRREGULAR ELASTIN lBERS
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vectastain ABC kit was implemented according to the 
manufacturer’s instructions (VectorLab, USA). Photo-
micrographs were taken with a black/white Axiocam 
MRm or color AxiocamICc3 camera mounted on 
Observer Z1 microscope (Carl Zeiss, Germany). Indi-
vidual staining types were reproduced three-times 
independently and for each studied parameter accord-
ing to the initial fixation, three to five animals per 
group were analyzed.
In order to evaluate the progress of tendon repair, 
H&E- or consecutive elastin-stained sections from 
five animals (each animal represented with three to 
five different slides consisting of three to four sections) 
were employed for microscopical scoring by four inde-
pendent observers in a blinded fashion. A point-based 
scoring system for histological and elastic fiber assess-
ment was used similar to Stoll et al. [23] with some 
modifications. The following parameters were scored 
and given points: (I) percentage of increase in cellular-
ity compared with NT; (II) percentage of increase in 
ectopic calcification; (III) percentage of vascularized 
areas versus total area; (IV) percentage of adipose-like- 
occupied areas; (V) percentage of poor fibrous areas; 
(VI) elastin fiber content (percentage increase) and 
morphology; and (VII) total score as the sum of points 
in parameters I-VI (Table 1).
Quantification of nuclear aspect ratio, 
orientation & density
In healthy tendon or in advanced stage of tendon heal-
ing, low numbers of cells with much flattened nuclei 
that are parallel-aligned to the tensile axis are typical 
features. To determine the aspect ratio of nuclei (NAR, 
defined as the ratio of the minor diameter to the maxi-
mal diameter) and cell density via nuclear count, 
DAPI images were analyzed using ImageJ software 
v1.45s with installed NII plugin (National Institutes 
of Health, MD, USA). First, by color threshold adjust-
ment the images were converted in black and white 
wherein DAPI-stained areas appear in black color and 
the remaining background in white color. Second, by 
implementing ‘analyze particles’ tool in NII plugin 
nuclear numbers and minor and maximal diameter 
for each nucleus were automatically calculated. Third, 
NAR were next calculated with GraphPad software 
and distributed by frequency as flattened cells are rep-
resented by NAR = 0, while rounded cells have NAR 
= 1. Cell density was expressed by calculating the 
 number of nuclei per mm2.
To determine nuclear orientation (by estimating 
angular deviation), H&E-stained images were ana-
lyzed with the following algorithm using the Axio-
Vision V4.8 software (Carl Zeiss): first, each image 
was converted to grey scale and nuclei were marked 
by adjusting the intensity segmentation threshold; 
second, nuclear orientation measurements were made 
with the ‘angular’ tool as the angle between the major 
axis of a nucleus and the longitudinal axis of the tissue 
were automatically given for manually selected nuclei. 
Nuclear orientation angle values of 0° represent a 
nucleus that is perfectly aligned along the longitudinal 
axis and as this value increases toward 90°, the nucleus 
becomes more angled to the long axis of the tendon.
Six to nine randomly taken 20× magnification 
images per section (within the area of injury 3 mm 
proximal from the calcaneus) of three to five animals 
per group were analyzed and a total number of approx-
imately 2000 nuclei were measured for NAR and den-
sity, while approximately 200 nuclei per group were 
evaluated for angular deviation.
X-ray analysis
Dissected hind limbs from the four study groups (ten 
animals/group) were screened for in-tendinous calcifi-
cation using x-ray imaging with a Cabinet x-ray Fax-
itron (Hewlett Packard, USA). Images were taken with 
32 kV, 2 mA and 2 s exposure time. White areas compa-
rable with the calcaneus represented calcified areas. The 
total area of calcification in each animal was digitally 
quantified in each Achilles tendon using the ‘polygonal’ 
tool of Image Pro Plus software v4 (Media Cybernetics, 
USA). In addition, mean value and standard deviations 
were calculated for each study group.
Polarized microscopic evaluation
Organized collagen type I fibers have strong birefrin-
gence property when exposed to polarized light; hence, 
they can be visualized in orange to yellow colors using 
microscopy. All 10 animals per group were prescreened 
and four representative animals/group were selected for 
the best quality of the H&E slides allowing for optimal 
and identical setting of the polarized microscopy imag-
ing. Each animal was represented with one slide con-
sisting of three sections. Microscopy was performed 
with 10× objective supplemented with a polarized filer 
mounted on Axioskope 2 microscope (Carl Zeiss). For 
optimal imaging the transmission axis of the analyzer 
was with an angle of 54° to the axis of the polarizer 
in the analyzes of all samples. In order to cover the 
entire tendon territory approximately 50 consecutive 
images/section were taken manually in a mosaic man-
ner and digitally stitched with Adobe Photoshop CS5 
software (Adobe System, CA, USA). Next, total Achil-
les tendon area (denominator) was measured in pixel 
with ‘magic wand’ tool and by using ‘color selecting’ 
tool the yellow-to-orange-positive pixels (numerator), 
corresponding to highly organized collagen areas, were 
automatically quantified. Final data were expressed 
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as a percentage of collagen birefringence and for each 
study group mean values and standard deviations were 
calculated.
Detection of the implanted human cells in rat 
Achilles tendons
For detection of the implanted hMSC-Mock or 
hMSC-Scx, tissue sections were stained with human-
specific (HLA)-ABC antibody as described above and 
in Supplementary Table 1. For the detection of human 
DNA in rat tendons genomic PCR-based method was 
used as follows: the material of five tissue sections from 
10 animals/group was scraped, collected and lyzed with 
20 mg/ml proteinase K in PCR buffer (Merck) overnight 
at 55°C. For controlling sample loading PCR for rat 
glyceraldehyde-3-phosphate dehydrogenase (rGAPDH, 
primers F5′-GACATGCCGCCTGGAGAAAC-3′ 
and R5′-AGCCCAGGATGCCCTTTAGT-3′) was 
performed using the following PCR program: 95°C/5 
min; 95°C/30 s; 56°C/30 s; 72°C/60 s; 72°C/1 min; 
as steps 2–4 38 cycles. PCR with human specific 
genomic primers for amelogenin X (AMELX, prim-
ers F5′-CAGCTTCCCAGTTTAAGCTCT-3′ and 
R5′-TCTCCTATACCACTTAGTCACT-3′ [24]) 
was performed with touchdown program: 94°C/5 
min; 94°C/30 s; 57°C/30 s; 4. 72°C/30 s; 94°C/30 
s; 47°C/30 s; 72°C/30 s; 72°C/5 min as steps 2–4 
10 cycles and steps 5–7 38 cycles. MGResearch PCR 
instrument (BioRad, Germany) was used. The PCR 
products were separated on 2% agarose gels, stained 
with ethidium bromide and visualized on a gel imager 
(Vilber Lourmat, Germany).
Data & statistics analysis
Quantitative data and statistical significance were ana-
lyzed with GraphPad Prism 5 software (GraphPad, 
CA, USA). In general, each group was segregated in 
two halves due to fixation procedures; then three to five 
animals per group were examined, but the total histol-
ogy slide and section numbers were kept equal between 
groups. In width, length, scoring and x-ray analyses 
all ten animals were evaluated. Bar charts show mean 
values and standard deviations. Multigroup statisti-
cal testing was performed with one-way ANOVA fol-
lowed by post hoc Dunnett’s test and t-test, and p-values 
< 0.05 were considered statistically significant.
Results
Engineered Achilles tendons with Scleraxis-
programmed tendon progenitors are superior 
in tissue appearance & composition
The gross morphological appearances of the Achilles 
tendons of the four experimental groups were evalu-
ated and documented post-dissection. We concluded 
that all tendon defect ends, including the ED group, 
were completely reconnected. Among the three injured 
groups, the healed Achilles tendons of the hMSC-Scx 
group had the best opalescent tissue appearance that 
resembled the native tissue (Figure 1B). According to 
our quantitative data, the hMSC-Scx group had sig-
nificantly smaller mean tendon width compared with 
the ED group (Figure 1C), whereas no significant dif-
ferences were found regarding the mean tendon length 
(Figure 1D).
For examination of the general tendon composition, 
organization as well as for overall assessment of the 
healing stage first, H&E (Figure 2A) and elastin stain-
ings and imaging of the four groups were performed. 
Afterward a qualitative evaluation of the degree of 
repair in all injured Achilles tendons was carried out 
by point-based scoring of the following parameters 
(Supplementary Figure 2): cellularity, ectopic calcifi-
cation, vascularized areas, adipose areas, poor fibrous 
areas and elastic fiber content and morphology. The 
results of four independent blinded observers are given 
in Table 1. Our scoring data clearly showed that the 
hMSC-Scx group (total mean of 18.01 and median of 
18.1) has the highest scores compared with the other 
injured groups (ED group: total mean of 14.87 and 
median of 14.75; hMSC-Mock group: total mean of 
14.97 and median of 15.5), indicating a superior com-
position of the healed Achilles tendons that is closer to 
the noninjured, healthy tendon NT group.
Very flattened cell nuclei, parallel alignment of the 
cells along the longitudinal strain axis and low cellu-
larity are characteristic features of healthy and fully 
repaired tendon tissue. To investigate these three 
aspects, first we quantified the frequency distribution 
of nuclei with different flatness factor. This was per-
formed by estimating the nuclear aspect ratio (NAR) 
as NAR, lower than 0.1 corresponds to completely flat-
tened/elongated nucleus of differentiated tenocyte-like 
cell. We found a tendency that the frequency of NAR 
lower than 0.1 in hMSC-Scx group was above 20% and 
thus higher than that of ED and hMSC-Mock groups 
(Figure 2B). Next, we studied and displayed the fre-
quency of the nuclear deviations of approximately 200 
nuclei/group in order to assess the cellular alignments 
within the Achilles tendons of the four study groups 
(Figure 2C). In a NT more than 70% of the nuclei are 
aligned in the range of 0–10° angles to the longitudi-
nal axis, another 25% of the nuclei are in the range 
of 10–20° angles. Interestingly, only in the hMSC-Scx 
group about 80% of the nuclei were within the angular 
deviation range of 0–20°, while in the ED and hMSC-
Mock groups more than 50% of the nuclei had angular 
deviation of 30–70°. This finding became even more 
apparent when we calculated the average and maxi-
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mum values of the nuclear orientation angles, which 
are shown in the circular sectors (Figure 2C). Only the 
hMSC-Scx group had average and maximum values 
very close to that of the control NT group. Last, we 
analyzed by automated nuclear counting the tendon 
cell density since at the time period of 16 weeks post-
surgery low cell density indicates advanced remodeling 
phase and overall healing process (Figure 2D). The cell 
densities within the engineered area of ED, hMSC-
Mock and hMSC-Scx groups were higher than the NT 
group, still the cellular density of hMSC-Scx Achil-
les tendons was significantly lower than the other two 
injured groups (Figure 2D).
Scleraxis-programmed tendon progenitors 
reduce the ectopic bone formation
Our study in 2013 [18] revealed in-tendinous calcifica-
tion in the repaired Achilles tendons, which we dis-
cussed is due to altered biomechanics of the injured 
tissue. Hence, it was very critical in our new model 
to examine if the implantation of hMSC-Scx cell will 
result in lowering the ectopic calcification. Using x-ray 
imaging and subsequent quantification, we can clearly 
demonstrate that indeed the hMSC-Scx group had the 
least degree of calcification in comparison to the ED 
and hMSC-Mock groups (Figure 3A & B). To further 
verify this substantial result we also performed immu-
nostaining for the classical bone-marker osteopon-
tin, which confirmed that the hMSC-Scx group had 
very negligible and scars osteopontin-positive areas 
(Figure 3C).
Since bone formation is closely related to vascular-
ization, we investigated for endothelial and macro-
phage-rich areas by immunohistochemistry against 
CD31 and CD68, respectively (Figure 3D & E). In the 
ED and hMSC-Mock groups, vessels were observed 
in the large calcified areas and in the tendon periph-
ery, while in the NT and hMSC-Scx groups vessels 
were rare and only at the tendon periphery and sheets. 
CD68-expressing cells were very seldomly observed 
within vessels in the ED, hMSC-Mock and hMSC-
Scx groups without any detectible difference, suggest-
ing their involvement in the gradual vessel obliteration 
rather than in inflammation.
Scleraxis-programmed tendon progenitors aid 
in enhanced tendon tissue maturation
Increase of collagen I to collagen III ratio, development 
of very organized collagen fibers with strong birefrin-
gence and enrichment of aligned and denser elastin 
fibers are hallmarks of advanced remodeling and late 
maturation phase of the tendon repair process [7]. This 
is paralleled with interchange of certain proteoglycans 
in the tendon matrix, namely reduction in biglycan 
(regulator of early and thin collagen fibril formation) 
and upregulation of decorin and lumican levels (reg-
ulators of late and thick collagen fibril formation) as 
well as a general drop in the deposition of mucopoly-
saccharides and nontendinous glycosaminoglycans/
proteoglycans [25,26]. Hence, to study whether implan-
tation of hMSC-Scx cells leads to faster tendon healing 
in terms of quicker entry into the maturation repair 
phase of the remodeling stage, we first analyzed the 
overall content of mucopolysaccharides and cartilage-
related glycosaminoglycans in the Achilles tendons of 
all groups by PAS and S.O./F.G. staining, respectively 
(Figure 4A & B). Among the injured groups, the ED 
group showed very strong positive PAS staining as well 
as several S.O/F.G-rich areas suggesting that the graft-
ing of cells gave an advantage in the tendon healing 
of the corresponding study groups. This inclination 
was further confirmed by polarized light microscopy 
analyses which demonstrated increased collagen bire-
fringence areas, equivalent of more mature colla-
gen fibers, in the Achilles tendons from the hMSC-
Mock and hMSC-Scx groups compared with the ED 
(Figure 5A & B). Last, detailed immunohistochemistry 
studies of six different antigens, precisely collagen 
type I and III, biglycan, decorin, lumican and elastin, 
revealed that their expression pattern in hMSC-Scx 
group resembled that of the NT group (Figure 6). This 
group had higher collagen I, decorin, lumican and 
elastin levels than the ED and hMSC-Mock groups. 
Very apparent difference was observed with regards to 
biglycan levels: ED group exhibited very high expres-
sion signals, while implantation of either hMSC-Mock 
or hMSC-Scx cells resulted in biglycan expression 
comparable to the levels in the NT group.
Altogether, based on our immunohistochemistry 
data, and together with the above-described results, we 
firmly concluded that implantation scaffold-free deliv-
ery of hMSC-Scx cells leads to advanced and superior 
healing in a very clinically relevant in vivo model of 
full-size Achilles tendon injury.
The implanted human cells integrate & can 
survive 16 weeks in vivo
To examine whether the implanted hMSC-Mock and 
hMSC-Scx cells were integrated in the Achilles ten-
dons and a portion of them has survived during the 
given healing period of 16 weeks, we performed first 
human-specific PCR on genomic DNA isolated from 
cryosections of the three injured groups, wherein the 
ED group served as negative control. In Figure 7A it is 
shown that in 9 out of 10 animals we detected human 
DNA only in the study groups that were implanted 
with cells. Next, by performing immunohistochemis-
try against the human HLA-ABC epitope, we localized 
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Figure 2. Detailed analyses of tendon tissue organization, nuclear aspect ratio, angular deviation and density. (A) Representative 
H&E mosaic images for each study group displayed different substructures in the Achilles tendons, the extent of which were scored in 
Table 1. (B) Frequency distribution of nuclear aspect ratio (NAR) (width vs length of nucleus). The black arrow indicates a tendency in 
NAR 0.0–0.1 increase in hMSC-Scx versus ED. (C) Frequency distribution and circular sector of maximum and average value of angular 
deviation (angle between individual nuclear axis and tendon tissue longitudinal axis). The black arrow indicates *p = 0.05 of hMSC-
Scx versus ED in 10°-20° deviation. (D) Representative black and white-converted images of DAPI staining and chart of calculated cell 
density. Bar charts present mean ± standard deviation; ***p = 0.0001 hMSC-Scx versus ED, ***p = 0.0006 hMSC-Mock versus ED and 
*p = 0.05 of hMSC-Scx versus Mock. Six to nine randomly taken 20× magnification images per section of three to five animals per 
group were analyzed and a total number of approximately 2000 nuclei were measured for NAR and density, while approximately 200 
nuclei per group were evaluated for angular deviation. 
A: Adipose areas; C: Calcaneus bone; EC: Ectopic calcification; F: Poor fibrous tissue; M: Muscle; T: Organized collagen fibers.
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Figure 3. Evaluation ectopic calcification and vasculature within the Achilles tendons of the four study groups. 
(A) Representative x-ray images (calcification indicated with arrow heads) and (B) plot of total calcified area in 
each Achilles tendon measured from the x-ray images. Mean values ± standard deviations (10 animals/group) are 
included as lines in the plot; *p = 0.05 hMSC-Scx versus ED and hMSC-Scx versus Mock. Representative images of 
the bone-osteopontin (C), the vessel/endothelial CD31 (left panels are 10x magnification, right panels are 40× 
magnification) (D) and the macrophage CD68 markers (E). Positively stained areas are in brownish color. Stainings 
were reproduced at least thrice independently and for each antigen sections from three to five animals/group 
were analyzed.
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single human cells incorporated within the proper of 
the Achilles tendons in hMSC-Mock and hMSX-Scx 
groups (Figure 7B).
Discussion
Due to the global population aging and weak regenera-
tive potential of tendons, age-related degeneration, var-
ious tenopathies, traumatic and sport ruptures, tendon 
conditions still present major challenges to orthopedic 
medicine. A novel approach to treat tendon injuries is 
with tissue engineering, in which cells, alone or in com-
bination with a scaffold, are introduced into the defect 
in order to enhance the repair and restore the original 
tissue function faster. In this approach a critical step is 
to identify the most appropriate cell type.
At present, the preferable cell types for musculoskel-
etal tissue engineering are adult MSC derived from 
bone marrow (BM) or adipose tissue (AD) [27–29], as in 
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Figure 4. Analyses of mucopolysaccharides depositions 
and cartilage glycosaminoglycans-rich areas in 
the Achilles tendons of the four study groups. 
Representative mosaic and magnified images of 
(A) Periodic Acid-Schiff (PAS, dark purple color) and 
(B) Safranin-O/Fast Green (S.O, orange to red color/F.G, 
green to light blue color) stainings. Both staining times 
were reproduced at least thrice independently with 
sections from five animals/group.
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particular the BM-MSC, being the best characterized, 
are still the most common cell source, because they 
are easily accessible and expandable, and can be dif-
ferentiated applying standardized protocols to at least 
three different mesenchymal lineages. However, there 
are several difficulties limiting the use of BM-MSC in 
tendon repair, such as ectopic ossification, bigger scar 
formation linked to high risk of adhesions and reduced 
MSC quality with donor age [30]. The results of our 
model demonstrated, in comparison to nonimplanted 
injured tendons, that delivery of MSC reduces the rate 
of in-tendinous ossification; however, among the two 
different cell types the hMSC-Scx group was superior. 
AD-MSC have become an alternative, very attractive 
cell source derived from plastic surgery, because of 
their low morbidity isolation procedure as well as lower 
risk of ectopic bone formation [30]. Studies have con-
cluded a better collagen fiber organization and over-
all improvement of the tendon structure when using 
AD-MSC for tendon therapy [31,32]; however, this 
cell type also faces few challenges including endog-
enous tendency toward adipocyte differentiation, 
purity levels of the primary cells and the possible side 
effects on the AD-MSC quality regarding background 
metabolic conditions [33]. For the above reasons, in 
the recent years, the field has turned its attention to 
tendon-resident stem/progenitor cells (TSPC) [13,34], 
which have been suggested to play a critical role in 
the proliferative and remodeling phase of tendon heal-
ing [11] and have the native propensity to terminally 
differentiate in tendon-specific cells [11]. Indeed in our 
previous study, using the same full size Achilles ten-
don injury model, the rat tendon-derived population 
outperformed the classical BM-derived cells in histol-
ogy and biomechanical analyzes [18]. Several hurdles 
are associated with the implementation of TSPC in 
tendon repair. On the technical/methodological side 
their purification and validation has proven difficult 
due to the lack of TSPC markers and their extended 
expansion has been linked to considerable phenotypic 
drift in vitro [35]. On the clinical side, the availability 
of tendon biopsies for TSPC isolation remains almost 
an unresolvable issue that is directly concomitant with 
patient comorbidity and longer preparatory procedures 
prior treatment, an issue that is further amplified with 
possible TSPC complications due to patient aging and/
or various disease conditions [13]. To overcome the dif-
ficulties associated with the use of TSPC, in 2012 we 
reported an alternative way to generate tendon pro-
genitors based on the one-step programming of the 
classical BM-derived MSC via the ectopic expression 
of the leading tendon transcription factor Scx [17]. It 
should be noted that our single cell-derived lines are a 
very useful standardized experimental model. For true 
clinical applications, it should be explored if transient 
Scx delivery in autologous MSC is sufficient for their 
stable programming into the tendon lineage. Others 
have shown alternative ways to induce tenogenic com-
mitment of hMSC; for example, overexpression of the 
late tendon marker EGR1 (early growth response-1) or 
BMP2  (bone morphogenetic protein 2 )/Smad8  or com-
bination of BMP12  and BMP13  [36–38]. Our previous 
work showed that subsequent to the involvement of the 
single early tendon factor Scx, hMSC underwent sev-
eral major changes, comprising of reduced self-renewal, 
restricted multipotential and upregulated expression 
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Figure 5. Microscopic evaluation and quantification of 
mature collagen fiber areas in the Achilles tendons. 
(A) Representative mosaic and magnified images of 
H&E-stained Achilles tendons under polarized light, 
wherein highly organized collagen fibers are visible 
in orange to yellow colors. (B) Quantification of total 
collagen birefringence (in percentage of total tendon 
area). Chart shows means ± standard deviations of four 
animals/group.
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of tendon-related genes, which collectively advocated 
their successful conversion into tendon progenitors [17].
Here, we can report for the first time that after 
in vivo implantation, our hMSC-Scx cells not only can 
form tendon-like structures, but can directly contrib-
ute to enhanced tendon healing in a clinically relevant 
Achilles tendon injury model. Based on two differ-
ent techniques for in vivo tracking, namely forensic 
genomic PCR and antibody-based detection, we could 
demonstrate that the human cells are retained within 
the implanted area and that a portion of these cells or 
their progeny can survive as long as 16 weeks post-sur-
gery. Moreover, via a combination of tissue morpho-
metric, x-ray, polarized light microscopic and various 
histological and immunohistological analyses of pro-
teins critical in tendon repair process we clearly showed 
that the hMSC-Scx group had smaller tendon diame-
ter, negligible ectopic calcification and advanced cellu-
lar organization and matrix maturation of the injured 
tendons, making this study group the closest to the 
native noninjured tendon. Hence, we concluded that 
hMSC-Scx implantation aids in advanced and superior 
remodeling stage of the tendon healing. Based on our 
encouraging results, we will aim in follow-up studies 
to additionally optimize the application of hMSC-Scx 
cells in terms of: developing a suitable tendon-specific 
scaffold for cell delivery in order to further augment 
the repair outcome; evaluating their potential in a big 
animal model followed by end point biomechanical 
testing in order to approximate to the tendon dimen-
sions of patient clinical scenarios; and establishing a 
transient viral or nonviral approach for Scx-program-
ming to surpass the safety concerns related to genetic 
modification of donor-derived human cells.
The positive effect of Scx in tendon healing has been 
suggested by three other studies. Gulotta et al. applied 
a transient adenoviral expression of Scx in MSC to treat 
tendon-bone insertions of detached by surgical cut rat 
rotator cuffs, and evaluated tendon healing in the pro-
liferative phase of 2 and 4 weeks. Despite the limited 
histological evaluation and lack of cell characterization 
and tracking, the main result was improved biome-
chanical strength in the Scx group [19]. Next, Tan et al. 
utilized, similar to our study, lentiviral delivery of Scx, 
but together with green fluorescent protein (GFP), in 
rat tendon-derived cells, in combination with fibrin 
glue and compared their healing potential to Mock 
(with GFP) and nontransduced cells in a patellar ten-
don window injury model with terminal analyses at 2, 
4 and 8 weeks. The authors concluded that the dou-
bly transgenic Scx/GFP tendon cells in comparison to 
Mock/GFP cells promoted tendon healing at the early 
stage. However, the data also suggested that the extent 
of repair after Scx/GFP cell implantation is much com-
parable to that of the nontransduced cells. Hence, it 
remains questionable if overexpression of Scx in native 
tendon-derived cells is beneficial and, as discussed 
above, a difficulty in the implication of such cells is 
the associated complications with their obtainment 
from patients’ prior therapy. In addition, it should be 
considered that in window defect models the neigh-
boring tendon regions stay intact, thus it is difficult to 
segregate the impact of local stem/progenitor cells to 
that of the implanted cells [21]. Last, Chen et al. tested 
the use of human embryonic stem cells (hESC), which 
were first differentiated to MSC, then engineered via 
lentivirus to express Scx and loaded onto silk-collagen 
sponge for repair of a gap wound model in rat Achil-
les tendons at 2 and 4 weeks [20]. The in vitro pheno-
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Figure 6.  Immunostainings of the tendon-related matrix proteins: collagen type I and III, biglycan, decorin, 
lumican and elastin (all in green color) and nuclear counterstain DAPI (in blue). All stainings were reproduced at 
least thrice independently including sections from three to five animals/group.
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typization of the hESC-MSC-Scx cells is in line with 
our first study [17]. At the two evaluated time points 
of early tendon healing, the Scx group was superior 
in terms of tissue organization and elastic modulus 
to the control GFP-transduced hESC-MSC group; it 
is unclear how approximating are the engineered ten-
dons to noninjured since such were not included for 
direct comparison. Furthermore, since tendon repair is 
a time consuming process, the evaluation of the long-
term effects of the cell therapy on tendon composition 
and strength, functional gain and repeated perfor-
mance or possible injury reoccurrence has to become 
a key goal in future studies. In sum, our investigation 
provides novel and promising findings that a scaffold-
free delivery of hMSC-Scx cells for the treatment of a 
clinically relevant Achilles tendon injury model results 
in advanced late remodeling stage and overall enhance-
ment of the tendon repair. Hence, we and others can 
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Figure 7. Detection of the implanted human cells in the rat Achilles tendons after 16 weeks in vivo. (A) By PCR for 
the human-specific amelogenin X (AMELX) gene using genomic DNA isolated from tendon tissue sections. Size of 
PCR product: 329 bp, and for simplicity not the actual animal number, but numbers 1–10 are given in the figure. 
For loading control PCR for rGAPDH was carried out. Size of PCR product: 92 bp. (B) By immunostaining for the 
human-specific antigen (HLA)-ABC. In the representative images positive human cells are in green color and the 
nuclear counterstain DAPI in blue color. PCR and stainings were reproduced twice with samples from 10 and five 
animals, respectively.
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strongly propose Scx-delivery as a therapeutic strategy 
to augment tendon healing.
Conclusion & future perspective
Scaffold-free hMSC-Scx cells implantation in injured 
Achilles tendons resulted in smaller size, negligible in-
tendinous ossification and advanced tissue maturation 
of the newly formed tendon, which collectively suggest 
that hMSC-Scx cells exert strong tendon-inducting 
and differentiating properties making them very well 
suited for reconstruction of full-size tendon defects. In 
future, in order for hMSC-Scx cells, or variants of this 
technology, to become a factual clinical tool in ortho-
pedics several open questions have to be addressed, 
such as possible combination and optimization with 
biomaterials/carriers; understanding the exact fate 
and survival rate of implanted cells; examining stable 
programming via transient Scx expression in autolo-
gous cells; long-term functional and biomechani-
cal performance tests in big animal models without 
immunosuppression; safety inspections behind the 
cell manipulation; and precise estimation of the time 
frame from patient hospitalization, preparation of 
the donors cells to exact point and technique of cell 
implantation. We believe that the present and forth-
coming results on the application of Scx-based cell 
therapy can lead to improve the outcome of tendon 
surgeries.
Executive summary
s  We explored the in vivo repair potential of tendon progenitors generated by a direct programming of 
mesenchymal stem cells with the transcription factor Scleraxis (hMSC-Scx cells).
s  We utilized our clinically relevant Achilles tendon injury model and implanted scaffold-free hMSC-Scx or 
control hMSC-Mock cells in the injured tendons; the tendon healing was compared with empty defect 
(ED) and noninjured, native tendons (NT) at 16 weeks post-surgery, a time point corresponding to the late 
remodeling phase of the repair process.
s  Via combination of morphometric, x-ray, polarized light microscopic and various histological and 
immunohistological analyses we found that the repaired tendons of hMSC-Scx group had smaller tendon 
diameters, negligible ectopic calcification and advanced cellular organization and matrix maturation, hence 
making this study group the closest to the NT.
s  Using two different methods for in vivo tracking, we also demonstrated that the human cells are retained 
within the implanted area and that a portion of these cells, or their progenitors, can survive 16 weeks in vivo, 
suggesting their direct contribution to the healing.
s  In sum, we can report that scaffold-free hMSC-Scx cell implantation aids in advanced and superior remodeling 
stage of the tendon healing and can be foreseen, after additional optimization steps, as a novel approach for 
therapy of tendon injuries.
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Abstract
Tendon’s natural healing potential is extremely low and 
inefficient, with significant dysfunction and disability due 
to hypocellularity and hypovascularity of tendon tissues. 
The application of stem cells can aid in significantly 
enhanced repair of tendon rupture; therefore, the main aim 
of this study is to assess the potential of using periodontal 
ligament cells (PDL), usually obtained from patients 
undergoing orthodontic treatment, as a novel cell source 
for cell-based therapy for tendon injuries in a clinically 
relevant rat full-size Achilles tendon defect. In addition, 
the study compares the differences between the healing 
effects of Achilles tendon-derived cells (AT) versus PDL 
and, hence, comprises of four experimental groups, native 
tendon (NT), empty defect (ED), PDL and human AT 
(hAT). The tendon healing in each group was assessed 
in the late remodelling phase at 16 weeks after surgery 
using a combination of methods, including evaluation 
of gross morphological appearance; various histological 
and immunohistological stainings; and detailed analyses 
of cell morphometry. Based on these outcome measures, 
PDL cell-implanted tendons exhibited not only advanced 
tissue maturation, less ectopic fibrocartilage formation, 
more organised collagen fibres, tendon matrix expression 
corresponding to the final healing stage, and better cell-
morphometry parameters when compared with the ED 
group, but were also very similar to the tendons treated 
with hAT-derived cells. Taken together, our study clearly 
demonstrates the feasibility of using PDL cells as a novel 
cell source for tendon repair and strongly recommends 
this cell type for the future development of innovative 
regenerative applications for treatment of different tendon 
or ligament pathologies.
Keywords: Periodontal ligament, Achilles tendon, cell-
based therapy, tendon repair, in vivo, immunohistochemistry, 
cell morphometry.
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Introduction
Tendons possess the capability to heal injuries in a process 
controlled primarily by local tendon cells, invading 
blood-derived cells and inducing expression changes in 
the surrounding extracellular matrix. Immediately after 
tendon injury, a scar formation is initiated, containing 
three overlapping stages: (1) tissue inflammation, (2) cell 
proliferation and (3) tissue remodelling (Docheva et al., 
2015). The final remodelling stage is time consuming 
and is characterised by a decrease in cellularity/density, 
significant cell shape flattening and almost perfect cell 
alignment to the axis of mechanical stretch, which is 
accompanied by maturation of collagen type I and elastic 
fibrils. Additional features of this stage are a decrease in 
biglycan and an increase in decorin and lumican protein 
expression (Juneja and Veillette, 2013). In parallel, collagen 
and elastic fibres start to organise along the longitudinal 
axis of the tendon, thereby restoring tendon stiffness and 
tensile strength (Sharma and Maffulli, 2005a).
 At present the options to heal injured tendons mainly 
consist of surgical intervention, tendon/ligament transfer 
or implantation of synthetic materials; however, they 
frequently result in unsatisfactory outcomes (Simonson et 
al., 2016). Hence, repair of tendon defects due to trauma 
or tendon degeneration remains as a great challenge to 
orthopaedic medicine. A promising new development 
of regenerative medicine is cell-based therapy, in which 
mostly stem cells are directly implanted or used for 
manufacturing of organoids – mimicking the original 
state of injured/diseased tissue. Such approach has been 
experimentally explored also for therapy of tendon injuries 
(Docheva et al., 2015). Scientists have mainly focused 
on two favourable cell types, namely bone morrow 
mesenchymal stem cells (BM-MSCs) and adipose-derived 
mesenchymal stem cells (AD-MSCs), because they are 
the best characterised and also fairly simple to obtain 
and expand in vitro. Interestingly, the most of the pre-
clinical animal studies concluded that MSC delivery can 
lead to increased cell proliferation, but these cells often 
differentiated towards osteoblasts or adipocytes within the 
tendon area, suggesting their inherent preference to commit 
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in the original lineage of the tissue from which they were 
isolated (Docheva et al., 2015). Subsequently, the native 
to the tendon-tenocytes, tendon stem/progenitor cells or 
tendon-derived fibroblasts became of great interest and 
their isolation has been successfully carried out (Bi et al., 
2007). However, the use of such autologous tendon-derived 
cells faces several concerns. For example, the patient has 
to undergo additional surgery to obtain a tendon biopsy 
for the purification of tendon cells causing comorbidity. 
Another concern is if the cells are to be isolated from the 
injured tendon they might be compromised in terms of 
quality and function (Docheva et al., 2015; Sharma and 
Maffulli, 2005b). Furthermore, the expansion of the tendon 
cells to sufficient numbers for implantation will require 
several weeks, in which the patient will be on hold or has 
to revisit the hospital numerous times.
 In the last years it has been recognised that MSCs 
exist in a wide range of tissue types, including dental and 
ligament tissues (Hakki et al., 2015; Lei et al., 2014; Liu 
et al., 2015). Periodontal ligament (PDL)-derived cells are 
of particular importance as in comparison to tendon cells, 
in a way that they are much more easily accessible through 
the oral cavity and can be simply harvested especially 
from extracted teeth when patients have orthodontic 
treatments (Miura et al., 2003; Seo et al., 2004). Recently, 
several groups, including our, reported that PDL contains 
endogenous stem/progenitor cells (Bluteau et al., 2008; 
Docheva et al., 2010; Ivanovski et al., 2006), which express 
tendon-specific genes such as scleraxis and tenomodulin 
(Docheva et al., 2010).
 The above findings strongly motivated us to investigate 
if PDL-derived cells can be used for cell-based therapy 
of tendon injuries. PDL cells hold several advantages to 
tendon-derived cells in regenerative applications, namely: 
easier obtaining and banking; avoiding additional surgery 
with potential risk for pain and infection and decreasing 
donor comorbidity. For this we designed not only an in 
vivo testing of the potential of PDL cells to form tendon-
like structures, but actually directly implanted the cells in 
a clinically relevant tendon injury model by utilising our 
established surgically created full-size tendon defects in 
rat Achilles tendons. In order to estimate the regenerative 
capacity of the PDL cells we compared the tendons 
receiving PDL cells to tendons implanted with Achilles 
tendon (AT)-derived cells as well as to non-implanted 
empty defect tendons. We assessed, by evaluation of 
gross morphological appearance, various histological 
and immunohistological stainings, and detailed cell 
morphometric analyses, how advanced is the healing 
process at 16 weeks after surgery and implantation, a 
time point corresponding to the late tendon repair phase. 
The results presented below strongly demonstrated that 
PDL cells contributed to tendon repair, which was very 
comparable to that of AT cells and far more superior to 
non-implanted tendons, hence concluding their feasibility 
as alternative cell source holding many advantages for 
therapy of tendon injuries.
Materials and Methods
Cell preparation prior implantation
In the study two standard cell lines characterised before, 
namely PDL-(hTERT) cell line from Docheva et al. (2010) 
and human AT-(hTERT) cell line derivative from Kohler et 
al. (2013) were implemented. Both cell lines were cultured 
in DMEM/Ham′s F-12 (1:1 mixture) medium supplemented 
with stable glutamine (365.3 mg/L), 1 × MEM amino 
acids (all from Biochrom, Berlin, Germany), 10 % FBS 
and 1 % L-ascorbic acid-2-phosphate (both from Sigma-
Aldrich, Steinheim, Germany) in a humidified incubator at 
constant 37 °C and 5 % CO2. Prior to implantation, the cells 
were expanded in three consecutive passages to 12 × 106 
corresponding to 1 × 106 cells per animal.
Animal model and surgical procedure
The surgical procedures were carried out according to our 
established in vivo model (Pietschmann et al., 2013). The 
procedures including animal handling prior, during and 
after surgery were approved by the Animal Care and Use 
Committee of the Bavarian Government (Animal Grant Nr. 
55.2-1-54-2531-58-08). Thirty athymic female Foxn1nu 
rats were purchased from Charles River Laboratories 
(Sulzfeld, Germany). Four different study groups were 
randomly selected (with ten animals per group): (1) native 
tendon (NT), non-injured left Achilles tendon; (2) empty 
defect (ED) control group, consisting of injured right 
Achilles tendon without cell implantation; (3) and (4) in 
which the animals received one-shot implantation of PDL- 
(PDL group) or hAT-cell pellets (hAT group) within injured 
right Achilles tendon, respectively. In the experimental 
design, in order to reduce numbers of animals sacrificed 
in the study, injury was applied to the right leg, while the 
left, non-injured was used as native tendon control.
 In brief, the surgical procedure consisted of: (1) 
animal anaesthesia was carried out; (2) the right Achilles 
tendon was exposed with a straight skin incision; (3) 
three millimetres of tissue from the Achilles tendon 
proper were resected by a surgical removal; (4) the defect 
was reconnected and stabilised with monofilament PDS 
(polydioxanone) 5-0 suture material by Kirchmayr-Kessler 
suture; (5) the original gap of 3 mm was kept and no end-to-
end was done in order not to shorten the tendon; (6) a three 
dimensional cell pellet of 1 × 106 cells was administrated 
into the defect site with a sterile pipette tip; and (7) the skin 
was sutured. After surgery the rats were allowed to walk 
freely in their cages and evaluated for tendon repair after 
16 weeks. For this all animals were sacrificed by euthanasia 
and gastrocnemius muscle-Achilles tendon-calcaneus bone 
units were retrieved after skin incision, imaged and total 
length of the total Achilles tendons and width of tendon 
proper of the Achilles tendons were manually measured.
Histology
Processing
The explanted gastrocnemius muscle-Achilles tendon-
calcaneus bone units were fixed either in 95 % ethanol/ 5 % 
absolute acetic acid overnight at 4 °C, or in 4 % 
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paraformaldehyde (PFA) (Merck, Darmstadt, Germany) 
(five animals in each fixation). After fixation, specimens 
were decalcified in 10 % EDTA/PBS pH 8.0 (Sigma-
Aldrich, Munich, Germany) for four weeks at room 
temperature, then embedded in tissue freezing medium 
(Jung, Leica, Nussloch, Germany) and cryosectioned at 
12 µm (Microm HM500 OM, Fisher, Walldorf, Germany). 
Prior use sections were stored at −20 °C.
Section hydration prior staining, dehydration and mount-
ing after staining
All the sections before staining were equilibrated to room 
temperature and hydrated with PBS 3 × 5 min then changed 
to deionised water. After following staining, Haematoxylin 
and Eosin (H&E), Safranin O & Fast Green (S.O/F.G.), 
Periodic Acid-Schiff (PAS) and 3,3 diaminobenzidine 
(DAB)-based staining, routine dehydration and mounting 
were carried out as follows: sections were washed through 
a graded ethanol series for 5 min each from 70 %, 80 %, 
90 %, then 100 % ethanol and xylene (Carl Roth, Karlsruhe, 
Germany) 2 ×5 min, and last mounted with Entellan 
mounting medium (Carl Roth, Karlsruhe, Germany).
H&E
Samples were placed in Haematoxylin (ready for use 
solution) (Carl Roth, Karlsruhe, Germany) in distilled 
water for 5 min, rinsed under deionised water for 5 min, 
washed in tap water for 7 min. Next, samples were 
immersed in Eosin (ready for use solution) (Carl Roth, 
Karlsruhe, Germany) for 5 min, changed to distilled water 
for 30 s, dehydrated and mounted.
S.O/F.G. & quantification
Samples were placed in 0.02 % Fast Green (Sigma-Aldrich, 
Steinheim, Germany) in 95 % ethanol for 12 min, rinsed 
under 1 % acetic acid in distilled water for 5 min, immersed 
in 0.5 % Safranin O (Sigma-Aldrich, Steinheim, Germany) 
in water for 15 min. Last, samples were rinsed quickly in 
90 % and 100 % ethanol and mounted. In order to cover 
the entire tendon territory, approx. 50 consecutive images/
section were taken and digitally stitched with Adobe 
Photoshop CS5 software (Adobe System, San Jose, CA, 
USA). Next, total Achilles tendon area (denominator) 
was measured in pixel with “magic wand” tool and 
by using “select colour range” tool the red-to-orange-
positive pixels (numerator), corresponding to sulphate 
glycosaminoglycans (GAGs) areas, were automatically 
quantified. Final data were expressed as a percentage of 
GAGs and for each study group mean values and standard 
deviations were calculated.
PAS
The PAS staining kit was obtained from Sigma-Aldrich. 
Samples were placed in periodic acid solution for 5 min, 
rinsed 3 times under distilled water, immersed in Schiff’s 
reagent (St. Louis, MO, USA) for 15 min, washed in 
running tap water for 5 min. Next, samples were stained 
in haematoxylin solution for 90 s, rinsed in running tap 
water, dehydrated and mounted.
 All stainings were reproduced thrice independently as 
three to five animals/group were analysed.
Immunohistochemistry
Antibodies
Primary: biglycan (ab58562, 1:30 dilution), collagen I 
(ab34710, 1:100), collagen III (ab7778, 1:50) and elastin 
(ab21610, 1:30, all from Abcam, Cambridge, UK); decorin 
(sc-22753, 1:30) and lumican (sc-33785, 1:50) (both 
from Santa Cruz, Heidelberg, Germany); osteopontin 
(MPIIIB101, 1:20, DSHB, Iowa City, IA, USA); 
(HLA)-ABC (M0736, 1:30, Dako, Glostrup, Denmark). 
Secondary: anti-goat Cy3 (705-165-147, 1:500), anti-rabbit 
FITC (111-095-144, 1:500), anti-mouse Cy3 (115-165-146, 
1:500) (all from Jacksonimmuno, West Grove, PA, USA) 
and anti-mouse vectastain ABC kit (PK-4002, 1:250, 
VectorLab, Peterborough, UK).
Immunolabelling procedure
Selected sections were treated with 2 mg/mL hyaluronidase 
(Sigma-Aldrich, Steinheim, Germany) for 30 min at 
37 °C. After washing and blocking, either with 2 % 
skimmed milk (Sigma-Aldrich, Steinheim, Germany) /
PBS or 2 % BSA (Sigma-Aldrich, Munich, Germany) /
PBS, primary antibodies were applied overnight at 4 °C. 
Next day, corresponding secondary antibodies were used 
for 1 h. For immunofluorescence-based experiments, 
sections were shortly counterstained with 4’,6-diamidino-
2-phenylindole (DAPI) (Life technology, Carlsbad, CA, 
USA) and mounted with Fluoroshield (Sigma-Aldrich, 
Munich, Germany). For DAB-based experiments, an 
initial quenching step was performed using 4 % H2O2/
methanol for 30 min at room temperature, and afterwards 
the classical vectastain ABC kit was used according to 
the manufacturer’s instructions (VectorLab, Eching, 
Germany), then sections were dehydrated and mounted.
 All stainings were reproduced thrice independently 
with three to five animals/group analysed.
ELISA quantification of collagen type I, biglycan and 
lumican protein expression
PFA-fixed sections mounted on microscope slides (90 
sections each animal, 5 animals per group) were used 
for protein extraction. Briefly, only Achilles tendon area 
was collected manually by scalpel. The tissue material 
was lysed in extraction buffer, composed of 8 M urea 
(Merck, Hohenbrunn, Germany), 50 mM Tris-HCl (Merck, 
Darmstadt, Germany), 1 mM EDTA (Carl Roth, Karlsruhe, 
Germany), 1 mM DTT (BIO-RAD, Munich, Germany), by 
incubation at 4 °C for 30 min, followed by centrifuged for 
20 min at 1 × 104×g, and supernatants containing protein 
extracts were stored at −20 °C until further use. Protein 
concentration was determined using the Micro BCA 
Protein Assay Kit (Thermo, Rockford, IL, USA) according 
to the manufacturer’s protocol. The protein samples were 
normalised between animals and further diluted 1:50 in 
order to lower the antigen concentration to the detection 
range of the ELISA kits. Commercially available ELISA 
kits for collagen type I (LS-F4691) biglycan (LS-F15938, 
both from LifeSpan BioScience, Seattle, WA, USA) and 
lumican (CSB-EL013234RA, Cusabio Biotech, College 
Park, MD, USA) were used following the manufacturer’s 
instructions and twice independently reproduced with 5 
animals per group.
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Quantification of collagen type III
An automated quantitative image analysis was performed 
as described in McCloy et al. (2014) with slight 
modifications. In brief, using ImageJ (National Institutes 
of Health, Bethesda, MD, USA) the following algorithm 
was applied: (1) nine randomly 10× magnification images 
were taken within the area of injury; (2) area of interest was 
manually designated using the “drawing/selection” tool; 
(3) “set measurements” for area, integrated density and 
mean grey value was selected from the analyse menu; (4) 
last the corrected total cryosections fluorescence (CTCF) 
representing the collagen III expression was exported and 
calculated in Excel (Microsoft) as follows CTCF = media 
of integrated density − media of the selected area × mean 
fluorescence. Three animals per group (each with nine 
images) were analysed.
Elastic fibres scoring
A point-based scoring system for elastic fibres assessment 
was used according to Hsieh et al. (2016) and legend of 
Table 2. Elastin-stained sections from three animals (each 
animal represented with 3 to 5 different slides consisting of 
3 to 4 sections) were employed for microscopical scoring 
in a blinded fashion.
Classical microscopy
Photomicrographs of H&E, S.O/F.G., PAS, DAB-based 
stainings were taken with a colour AxiocamICc3 camera, 
while images of immunohistochemical stainings were 
taken with a black/white Axiocam MRm camera, both 
mounted on Observer Z1 microscope (Carl Zeiss, Jena, 
Germany).
Polarised microscopy & evaluation
H&E-stained sections from the 4 study groups (3 animals 
per group and each animal represented with 3 different 
sections) were imaged using 10× objective supplemented 
with polarised filter mounted on Axioskope 2 microscope 
(Carl Zeiss, Jena, Germany). Under this filter, organised 
collagen type I fibres can be visualised in orange to 
yellow colours when exposed to polarised light. For final 
representation, consecutive images of the whole unit of 
gastrocnemius muscle-Achilles tendon-calcaneus bone 
were digitally stitched together with Adobe Photoshop 
CS5 software (Adobe System).
 Organised collagen type I fibres have strong 
birefringence property when exposed to polarised light; 
hence, they can be visualised in orange to yellow colours 
using microscopy. Microscopy was performed with 10× 
objective supplemented with a polarised filter mounted 
on Axioskope 2 microscope. For optimal imaging the 
transmission axis of the analyser was with an angle of 54° 
to the axis of the polariser in the analyses of all samples. 
In order to cover the entire tendon territory, approx. 
50 consecutive images/section were taken manually 
in a mosaic manner and digitally stitched with Adobe 
Photoshop CS5 software (Adobe System). Next, total 
Achilles tendon area (denominator) was measured in pixel 
with “magic wand” tool and by using “colour selecting” 
tool the yellow-to-orange-positive pixels (numerator), 
corresponding to highly organised collagen areas, were 
automatically quantified. Final data were expressed 
as a percentage of collagen birefringence and for each 
study group mean values and standard deviations were 
calculated.
Quantification of nuclear aspect ratio and density
Determination of cell density by nuclear count and 
aspect ratio of nuclei (NAR, defined as the ratio of the 
minor diameter to the maximal diameter) was performed 
with the following algorithm: (1) 9 randomly taken 20× 
magnification DAPI-stained images within the area of 
injury, 3 mm proximal from the calcaneus, for 3 to 5 
animals per group were taken; (2) DAPI images were 
analysed using ImageJ software v1.49 with installed NII 
plugin (National Institutes of Health, Bethesda, MD, USA); 
(3) each image was converted to greyscale by colour 
threshold adjustment (DAPI-stained areas in black and 
background in white); (4) the total number of nuclei/image 
and the minimal and maximal diameter for each nucleus 
were automatically measured by “analyse particles” tool 
in NII plugin; (5) the obtained values were exported to an 
Excel spreadsheet (Microsoft); (6) average cell density 
per group was expressed by calculating the mean number 
of nuclei per mm2; (7) NAR was calculated in Excel 
and distributed by frequency using GraphPad Prism 5 
software (GraphPad, La Jolla, CA,USA). Rounded cells 
are represented by NAR = 1, while flattened cells have NA 
= 0 and all nuclei/group were assessed calculation of NAR.
Quantification of nuclear orientation
To determine nuclear orientation by estimating angular 
deviation, H&E-stained images were analysed using the 
AxioVision V4.8 software (Carl Zeiss, Jena, Germany). Six 
randomly taken 20× magnification images for 3 to 5 animals 
per group were analysed and a total number of approx. 200 
nuclei/group was evaluated for angular deviation. The 
angle measurements between the longitudinal axis of the 
tissue and the major axis of a nucleus were automatically 
given with the “angular” tool for manually selected nuclei. 
The angular deviation was distributed by frequency 
with GraphPad Prism 5 software (GraphPad). Nuclear 
orientation angle with values of 0° represents a nucleus 
that is perfectly aligned along the longitudinal axis and 
as this value increases when the nucleus becomes more 
angled to the long axis of the tendon.
X-ray analysis
In-tendinous calcification was screened in dissected hind 
limbs from the four study groups (ten animals/group) using 
X-ray imaging with a Cabinet X-ray Faxitron (32 kV, 2 mA 
and 2 s exposure time, Hewlett Packard, McMinnville, 
OR, USA). The total area of calcification in each animal 
was digitally quantified from X-ray images using the 
“polygonal” tool of Image Pro Plus software v4 (Media 
Cybernetics, San Diego, CA, USA). Mean value and 
standard deviations were calculated for each study group 
(ten animals/per group) with GraphPad Prism 5 software 
(GraphPad).
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Data and statistics analysis
Quantitative data and statistical significance analyses were 
done with GraphPad Prism 5 software (GraphPad). Bar 
charts show mean values and standard deviations. Multi 
group statistical testing was performed with one-way 
ANOVA followed by post-hoc Dunnett’s test and a p-value 
of < 0.05 was considered statistically significant.
Results
Gross and morphological appearance of Achilles 
tendons after cell implantation
After 16 weeks of surgery the gross appearance and 
morphological organisation of the Achilles tendons were 
assessed by imaging, length and width measurements and 
H&E stainings. The tendon defect ends were re-connected 
in all injured groups, including the ED group. However, 
the Achilles tendons of the PDL and hAT groups had more 
opalescent tissue appearance in comparison to the ED 
group (Fig. 1a). Furthermore, according to our quantitative 
data, these two groups exhibited smaller mean tendon 
width compared to the ED group, whereas no significant 
differences were found regarding the mean tendon length 
(Table 1). H&E-stained mosaic imagining of the four 
experimental groups were performed (Fig. 1b) and used for 
examination of the overall morphological organisation and 
composition of different tissues sub-areas such as tendinous 
regions (from the NT group), areas of high cellularity, 
ectopic calcification, and adipose deposition (from the 
ED group) (Fig. 1c). In the control native Achilles tendons 
(Fig. 1b, NT), well organised parallel collagen fibres are 
clearly visible; the tendon tissue is very homogeneous 
with low number of cells, while some adipose and loose 
connective tissue can be found on the outer side of the 
Achilles tendons. In contrast, in the ED group large 
ossified and vascularised areas surrounded with poorly 
organised fibrous tissues containing high cell numbers 
as well as occasionally fatty deposits were characteristic 
features (Fig. 1b, ED). The cell-implanted PDL (Fig. 1b, 
PDL) and hAT (Fig. 1b, hAT) groups were very similar 
to each other and when compared to the NT group, they 
were clearly larger and more heterogeneous. The Achilles 
tendons in these groups were mostly composed in the 
periphery of larger tendinous areas with well-organised 
collagen fibres and in the centre with more fibrous regions 
with higher cellularity indicating still ongoing tissue 
remodelling. However, ectopic calcification formation 
appeared scarce and smaller in size, which represented a 
major difference between PDL and hAT groups to the ED 
group. This first assessment of the PDL-implanted Achilles 
tendons suggested that this group performs comparably to 
the hAT group, but also is superior to the non-implanted 
injured tendon group, ED. To fully validate our initial 
observations, we carried out detailed molecular analyses 
of the ectopic calcification and tendon matrix composition 
as well as assessment of characteristic cellular features by 
cell morphometry quantifications.
Evaluation of ectopic calcification formation
In order to carefully compare the in-tendinous 
ossification we first analysed the overall content of 
related to the initial fibrocartilage glycosaminoglycans 
and mucopolysaccharides by S.O/F.G. and PAS staining of 
all groups (Fig. 2a and Fig. 2b). A drop in the deposition 
of non-tendinous glycosaminoglycans/proteoglycans 
and mucopolysaccharides is an indication for advanced 
remodelling and entry in the maturation phase of the 
tendon repair process. Among the three injured groups, 
S.O/F.G.-rich areas and very strongly positive PAS staining 
were detected only in the ED group mainly around the 
ectopic calcification areas. This observation was further 
confirmed by quantification of S.O-positive area (Table 
2). Then, by using an antibody directed against the bone 
Table 1. Mean length and width of the four 
study groups.
Values present mean ± standard deviation; 
* p = 0.03 PDL vs. ED and ** p = 0.0074 hAT 
vs. ED.
Study group Length [cm] Width [mm]
NT 1.14 ± 0.12 1.60 ± 0.23
ED 1.32 ± 0.14 3.38 ± 0.59
PDL 1.32 ± 0.10 2.84 ± 0.36*
hAT 1.34 ± 0.14 2.65 ± 0.49**
Table 2. Quantification of S.O.-positive area, calcified area and total collagen birefringence and scoring of elastic 
fibres.
Quantification digital image analysis of S.O. stainings, X-ray and polarised light microscopy. Scoring was done 
in a blinded fashion using the following point system: for content the total amount of elastin fibres (non-mature 
or mature) compared to NT was estimated by 4 points = 0-25 %, 3 points = 26-50 %, 2 point = 51-75 % and 
1 point = 76-100 %, for elastic fibres morphology 4 points = mature, thin parallel elastic fibres, while 1 point 
= non-mature, thick irregular elastic fibres.
Study group
S.O. positive area 
[%]
Calcified area
[mm2]
Total collagen 
birefringence [%]
Scoring of elastic fibres
Content Morphology
NT 2.83 ± 0.96 0 ± 0 81.34 ± 9.07 4 4
ED 15.46 ± 5.88 3.79 ± 1.04 24.15 ± 9.53 2.25 1.25
PDL 7.50 ± 4.11 2.45 ± 0.73 30.87 ± 8.51 3 3
hAT 11.03 ± 2.59 2.98 ± 0.90 33.88 ± 9.36 3 3.5
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marker osteopontin (Fig. 2c) and by quantifying the mean 
area of ectopic calcification on X-ray images of 10 animals 
per group (Table 2) it was revealed that the dimensions of 
calcification in PDL and hAT group are very comparable. 
Due to detected in-group variability, no significant 
difference but a tendency was found to ED group in terms 
of ossification. In total, the above analyses revealed that the 
implantation of either PDL or hAT cells was advantageous 
for the tendon healing process.
Expression and organisation of collagen and tendon-
related matrix proteins
We analysed the expression of the two major collagens, 
namely collagen I and III that are critically involved 
Fig. 1. Overall appearance and tissue morphology of the Achilles tendons in the four study groups. (a) Representative 
gross morphological images and (b) representative H&E mosaic photomicrographs of NT, ED, and PDL- and hAT-
implanted Achilles tendons after 16 weeks of healing. (c) Examples of H&E micrographs demonstrating different 
tissue sub-areas such as tendinous areas (from NT group), areas of high cellularity, ectopic calcification, and adipose 
deposition (from ED group) in the Achilles tendon explants.
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during tendon healing. Our results showed that the PDL 
and hAT groups had higher immunofluorescence signals 
for collagen type I and lower signals for collagen type III 
than the ED group (Fig. 3a and b). This observation was 
further confirmed by polarised light microscopy (Fig. 
3c) and quantitative analyses (Table 2), demonstrating 
increased collagen birefringence, equivalent of more 
superior organised and mature collagen fibres, in the 
Achilles tendons from the PDL and hAT groups compared 
to the ED. To quantify collagen type I (Fig. 3d) and III (Fig. 
3e) expression, we next carried out ELISA and automated 
digital image analysis, respectively. The quantitative 
evaluation demonstrated that the concentration of collagen 
type I was significantly higher in the hAT group followed 
by the PDL. With regards to collagen III expression, all 
injured groups had significantly higher levels than NT 
group. A tendency for lower collagen III expression in 
PDL group was detected (Fig. 3e).
 Then, immunofluorescence-based studies of four 
different antigens – biglycan, decorin, lumican and 
elastin – were carried out (Fig. 4a and Table 2). In general, 
advanced remodelling and the late maturation phase of 
the tendon repair process is characterised not only by 
decreased ratio of collagen type III to collagen type I but 
also by reduction in biglycan (regulator of early and thin 
collagen fibril formation) and upregulation of decorin, 
lumican (regulators of late and thick collagen fibril 
formation) and elastin levels. Such molecular pattern is 
typical for the control non-injured NT group. The exact 
biglycan and lumican protein levels were measured with 
target-specific ELISA. The obtained quantification data 
not only confirm the immunofluorescence results, but 
also revealed a significantly lower biglycan (Fig. 4b) and 
significantly higher lumican (Fig. 4c) expression in PDL 
and hAT groups. Finally, scoring of elastin fibres contend 
and morphology suggested pattern more close to the NT 
in PDL and hAT groups.
 All in all, our analyses of the selected proteins revealed 
in the PDL group a tissue composition very comparable 
to hAT group, and furthermore closer to the NT group. In 
contrast, ED group exhibited high levels of biglycan and 
low levels of decorin, lumican and elastin. Altogether, 
based on our investigation outcomes we concluded that the 
PDL group, similar to the hAT group, has more mature and 
organised matrix protein composition than the ED group.
Cell morphometric analyses
The above described changes of the tendon matrix in 
advanced stage of tendon healing are further accompanied 
with lowering of cell density, cell flattening and parallel 
alignment to the tensile axis. Therefore, we first evaluated 
cell density in the four experimental groups by performing 
nuclear counting on DAPI images and found that the cell 
densities of PDL- and hAT-implanted Achilles tendons are 
significantly lower than the ED group (Fig. 5a). Next, we 
assessed cellular alignment by analysing the frequency 
distribution of angular degrees of cells within the Achilles 
tendons of the four study groups. In the NT group more 
than 95 % of the nuclei were aligned in the range of 0-20° 
angle to the longitudinal tendon axis. In the PDL and hAT 
groups about 60 % of the nuclei were within the angular 
deviation range of 0-20°, while in the ED more than 60 % 
of the nuclei had angular deviation of above 30° (Fig. 
5b). Finally, we quantified the frequency distribution of 
the nuclear aspect ratio (NAR), which directly reflects 
the flattening of cells (Fig. 5c), and found in NT group 
Fig. 2. Analyses of glycosaminoglycans- and mucopolysaccharides-rich areas and ectopic calcification in the Achilles 
tendons. (a) Representative mosaic and magnified images of Safranin O (S.O, orange to red colour)/ Fast Green (F.G., 
green to light blue colour), (b) Periodic Acid-Schiff (PAS, dark purple colour) and (c) bone marker protein – osteopntin 
stainings. All staining were reproduced thrice independently with sections from 5 animals/group.
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that the majority of the cells, approx. 85 %, have NAR of 
0.0-0.2. Interestingly, in the PDL group the frequency of 
cells with 0.0-0.2 NAR was approx. 60 % and thus being 
higher than that of ED and even hAT groups, and moreover 
the frequency of cells with NAR 0.5-1.0 was very similar 
to that of NT group.
 To examine whether the implanted PDL and hAT cells 
were integrated in the Achilles tendon, we have performed 
cell tracking by staining with anti-human HLA-ABC 
antibody (Fig. 5d). No signals were observed in NT and 
ED groups as expected, while in the PDL and hAT groups, 
incorporated human cells surviving or being their progeny 
were detected suggesting direct contribution as well as 
long-term survival in the defect area.
 Taken together, based on the cell morphometry data 
together with the above-described results obtained in a very 
clinically relevant in vivo model, we firmly concluded that 
implantation of PDL cells aids in Achilles tendon healing 
that is on one side comparable to hAT cells and on the other 
more advanced and superior to the healing of ruptured 
non-implanted tendons.
Fig. 3. Expression and organisation of collagen proteins. (a) Collagen type I and (b) Collagen type III immunofluorescent 
stainings (in green colour) and nuclear counterstain DAPI (in blue). (c) Representative mosaic and magnified images 
of H&E-stained Achilles tendons under polarised light, wherein highly organised collagen fibres are visible in orange 
to yellow colours. All stainings were reproduced thrice independently, including sections from 3 to 5 animals/group. 
(d) Collagen type I levels were assessed by ELISA. Bar charts present mean ± standard deviation; ***p < 0.005, 
**p < 0.01. (e) The collagen type III protein expression was quantified by automated digital image analyses and 
expressed as CTCF (corrected total cryosection fluorescence) in arbitrary units (A.U.). Bar charts present mean 
± standard deviation; **p = 0.0025.
polarised light microscopy
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Discussion
The frequent failure of fully satisfying tendon repair 
following age-related degeneration and overuse tendon 
ruptures has encouraged the search for novel therapeutic 
approaches to enhance the healing process of tendons. A 
major theme in the ongoing strategies is in the application 
of stem cells in injured tendons (Lui and Ng, 2013; Oragui 
et al., 2012; Siddiqui et al., 2010). Stem cells can be simply 
defined as a cellular population with the ability to self-
replicate through mitosis to form daughter cell lines, which 
have the potential to terminally differentiate into a number 
of different cell lineages depending on the signalling milieu 
reaching these cells. In recent years, several tissues such 
as bone marrow, fat or tendons themselves have been 
identified as potential sources for obtaining stem cells for 
Fig. 4. Expression of key proteoglycans and elastin fibres. (a) Representative immunofluorescent images of the 
tendon-related matrix proteins biglycan, decorin, lumican and elastin (all in green colour) and nuclear counterstain 
DAPI (in blue) expressed in the Achilles tendons of the four study groups, NT, ED, PDL and hAT. All staining were 
reproduced thrice independently, including sections from 3 to 5 animals/group. (b) Biglycan and (c) lumican protein 
levels quantified by ELISA. Bar charts present mean ± standard deviation; ***p < 0.005, **p < 0.01.
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Fig. 5. Analyses of cell density, angular deviation, nuclear aspect ratio and in vivo tracking of the implanted human 
cells. (a) Representative black and white-converted images of DAPI staining and chart of calculated cell density. Bar 
charts present mean ± standard deviation; ***p < 0.0001. (b) Frequency distribution of angular deviation (angle between 
individual nuclear axis and tendon longitudinal axis); *p = 0.01 for PDL vs. ED and *p = 0.02 for hAT vs. ED for the 
frequency of 10-20 deviation. (c) Frequency distribution of nuclear aspect ratio (NAR, width vs. length of nucleus) 
in the four study groups, NT, ED, PDL and hAT. (d) Immunostaining for the human-specific antigen HLA-ABC. 
Representative images for three different animals per group where in positively stained human cells are in green and 
the nuclear counterstain DAPI in white.
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tendon repair. As mentioned in the introduction, up-to-date, 
each of these tissues faces several inevitable challenges. 
With regards to native tendon-derived cells, a clear 
advantage is that they can differentiate more efficiently 
directly into tenocytes rather than cells of other lineages. 
In our previous study (Pietschmann et al., 2013), where 
we established the clinically relevant full-size Achilles 
tendon defect model, we compared the healing potential 
of rat MSC versus rat-derived tenocytes. Based on our 
histological and biomechanical results demonstrating 
reduced central ossification, increased tendon-like areas 
in the site of injury and above all significantly improved 
ratio of failure strength to tendon cross-section, we strongly 
concluded that tendon-derived cells hold a clear advantage 
to MSC. However, one of the most critical issues with the 
use of tendon cells is the practical limitation behind their 
obtainment in clinical scenarios. Because of the much 
easier isolation procedure of periodontal ligament, which 
can be simply collected from removed teeth during usual 
orthodontic procedures, as well as the much comparable 
cellular features of ligamentous and tendinous cells, we 
hypothesised that PDL could provide a uniquely well-
suited cell source for tendon repair. Hence, in this study 
we utilised, the previously established by us and evaluated, 
the healing impact of PDL-derived cell line versus 
control Achilles tendon-derived cell line (hAT). The main 
advantages of using cell lines in our experimental model 
are: being well-characterised, allowing standardisation of 
the methods and expansion to high cell numbers. However, 
as discussed below such cell lines are only the first steps in 
establishing a potent clinical translation protocol because 
they cannot represent donor variability and be used in 
patients.
 The two study groups, PDL and hAT were compared 
to non-implanted, but surgically ruptured Achilles tendons 
(ED group) at 16 weeks postoperatively. This time point 
corresponded to the late remodelling phase of the tendon 
healing course wherein major molecular events affecting 
matrix maturation, cellular organisation and transforming 
the initial fibrous template to the tissue pattern of healthy 
tendon are taking place. Based on the combination of tissue 
and cell morphometric, polarised light microscopic, various 
histological and immunohistological analyses we found 
that the PDL group is characterised by smaller tendon 
diameter, better tissue morphology, advanced matrix 
maturation and cellular organisation compared to the ED 
group. This study group was very similar to the control 
hAT group and both together resembled in several of the 
studied parameters the NT group. Moreover, in vivo cell 
tracking demonstrated that the implanted human cells or 
their progeny can integrate and survive long-term at the 
side of injury suggesting direct contribution to the healing 
process. In sum, we can report that PDL-derived cell 
implantation results in advanced and superior remodelling 
stage of tendon healing and can be foreseen as a novel 
alternative to tendon cell source to treat tendon injuries.
 The implemented cell lines in our study serve as a great 
experimental model because they allowed standardised 
investigation to validate our hypothesis that PDL-derived 
cells are suitable source for tendon healing. This first 
step on selecting a high potential cell source in clinically 
relevant full-size Achilles tendon defect in a small animal 
model provides the translational bases for designing a 
true clinical application. The second step should focus on 
scaling up to comparable tissue dimensions in big animal 
model such as pig, and using autologous derived PDL 
cells. Finally, to further speed up the healing, a possible 
combination of PDL cells with suitable biomaterial carrier 
should be considered. In such future studies in-depth 
histological assessment should be combined with key 
biomechanical measurements and functional performance 
tests with long-term follow up.
 Our novel findings are in line with a recent study by 
Moshaverinia et al. (2014), who investigated the capacity 
of two dental tissue-derived cells, periodontal ligament 
stem cells (PDLSCs) and gingival mesenchymal stem 
cells (GMSCs) to form tendon-like structures in vivo. The 
two different cell types were transplanted subcutaneously 
into mouse dorsal surfaces and the ectopic neo-tendon 
regeneration was evaluated by qPCR measurements for 
biglycan, decorin and tenomodulin after 4 weeks and then 
after 8 weeks by histological and immunohistochemical 
stainings for tendons-specific protein markers. The authors 
concluded that PDL as well as GM stem cells can contribute 
to tendon-like formation in vivo. In this respect, our study 
presents the next progress step in assessing the healing 
potential of PDL cells since it demonstrates for the first 
time that they can indeed enhance the repair of full-size 
tendon ruptures in a manner that is very comparable to 
native tendon-derived cells.
 Similar to PDL cells, researchers have dealt with other 
cell types that also have easier accessibility; for example, 
MSC from human bursa tissue that can be obtained from 
patients undergoing rotator cuff surgery (Song et al., 2014) 
and induced pluripotent stem cells (Xu et al., 2013) that can 
be generated by genetic modifications and banked in high 
numbers. Moreover, these studies have demonstrated that 
these cells exhibit a high potential for application in tendon 
repair. However, at present their use is associated with 
low efficiency of in vitro expansion; issues with allogenic 
transplantation; phenotype stability and differentiation 
control. PDL is a novel attractive cell source because it can 
be obtained from exfoliated deciduous teeth of children 
aged 5 onwards and from sound teeth that are normally 
discarded in frequent routine orthodontic procedures 
(premolars in class II malocclusion or wisdom teeth 
removal) in dental clinics. Patient-specific PDL-derived 
cells can be easily harvested by scratching the surface of the 
root and in vitro pre-expanded to high numbers in culture 
with simple standard procedures. Possible bacterial, fungal 
or mycoplasma contamination can be easily controlled by 
using antibiotics, antifungal agents or elimination kits. 
Harvested PDL cells can thereafter be banked up for years 
ahead and last the phenotype of the cells is very similar 
in nature to tendon cells, hence no complicated genetic 
or growth factor manipulations are required. Therefore, 
the PDL can be considered an ideal source for stem 
cell banking purposes and be used in therapy of tendon 
injuries. Several open questions remain to be clarified in 
following investigations such as the possible combination 
of PDL cells with suitable biomaterials; the scaling up to 
dimensions similar to human tendon injuries; the reached 
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biomechanical strength; the risk of PDL cell quality loss 
after long-term storage; the exact technique and time 
point of application; and the prognosis on periods for 
patient hospitalisation and post-operative physiotherapy. 
It will be of great interest, by using adequate animal 
models, to examine wheatear PDL-derived cells are also 
suitable for prevention or therapy of tendon/ligament 
degenerative diseases, that are occurring prior rupture, and 
for periodontitis. We believe that further research on these 
questions will be critical to translating our animal model 
to potential clinical applications.
Conclusions
In this study, the effect of PDL for cell-based therapy of 
tendon injuries was investigated using an in vivo model of 
a full-size rat Achilles tendon defect. Our in-depth results 
demonstrated that PDL cell-implanted tendons exhibited 
not only advanced tissue maturation, less ectopic bone 
formation, more organised collagen fibres, tendon matrix 
expression corresponding to the final healing stage and 
better cell-morphometry parameters when compared with 
the ED group, but were also very similar to the tendons 
treated with hAT-derived cells. Taken together, our study 
clearly demonstrates the feasibility of using PDL cells 
as a novel cell source for tendon repair and strongly 
recommends this cell type for the future development 
of innovative regenerative applications for treatment of 
different tendon or ligament pathologies.
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Discussion with Reviewer
Christopher Niyibizi: For future clinical application, PDL 
cells would be harvested from different individuals, is there 
a worry for potential immune response to the donor cells 
by the recipients?
Authors: We foresee the use of PDL cells in two applicative 
modes: autologous or allogeneic. The autologous PDL cell 
implantation eliminates problems with immune rejection 
of the grafted material. In cases of low harvest of PDL 
cells allogeneic PDL cell implantation comes in question. 
Interestingly, two studies have already demonstrated 
that PDL-derived stem/progenitor cells possess low 
immunogenicity and actually can play immunomodulatory 
roles. Ding et al. (2010), observed no immune rejection 
of allogenic PDL cells transplanted in a swine model of 
periodontitis. Kim et al. (2010) showed that human and 
canine PDL cells have profound immunomodulatory effect 
(inhibition of cell division) on human peripheral blood 
mononuclear cells. The above results suggest that PDL 
donor cells can circumvent immune rejection; however, 
follow up xenogenic in vivo studies are necessary to 
strengthen such findings prior clinical testing.
Additional References
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Editor’s note: The Scientific Editor responsible for this 
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